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Abstract 
Gonadotropin-releasing hormone (GnRH) binds to GnRH receptors (GnRHR) in the 
pituitary and stimulates release of gonadotropins, which control reproduction. It has been 
proposed that the congenital Glu
2.53(90)
Lys GnRHR mutation causes infertility by disrupting a 
salt-bridge important for GnRHR protein expression. To investigate its role
 
in GnRHR 
function, Glu
2.53(90)
 was mutated to residues that mimic or remove its side-chain properties. 
Mutant receptors were assessed for inositol phosphate signaling and radioligand binding. 
Receptors with small or negatively-charged substitutions for Glu
2.53(90) 
exhibited no 
measurable function. Stabilizing receptor expression by appending a carboxy-terminal tail 
recovered function of the Glu
2.53(90)
Lys and Glu
2.53(90)
Ala GnRHRs, but not the conservative 
Glu
2.53(90)
Asp mutant. Receptors with uncharged (Gln) or hydrophobic (Leu, Phe) 
substitutions that cannot form salt-bridges with Lys
3.32(121) 
were fully functional. Although the 
positively-charged Arg substitution decreased binding affinity, it preserved GnRHR function, 
confirming that interaction with the positively-charged Lys
3.32(121)
 is not required. Comparing 
the GnRHR with structurally-related G protein-coupled receptors revealed that the equivalent 
residue of rhodopsin, Met
2.53(86)
, interacts with Trp
6.48(265)
. Mutating Trp
6.48(280) 
of the GnRHR 
to Ala and Arg disrupted GnRH-stimulated function, confirming a role in expression. The 
Trp
6.48(280)
Arg GnRHR with an appended carboxy-terminal tail had decreased GnRH binding 
affinity. The preserved function of mutant receptors with large hydrophobic or positively-
charged amino acid substitutions suggests that the size of the Glu
2.53(90) 
is important for 
stabilizing GnRHR structure. Decreased affinity of mutant receptors with larger (Arg) 
substitutions for Glu
2.53(90) 
and Trp
6.48(280) 
suggest that both residues make conserved 
intramolecular interactions that stabilize receptor protein expression and configure the 
extracellular GnRHR structure.  
(250 words)  
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1. Chapter 1: Introduction and literature review 
1.1. Development of human reproductive function 
Human reproductive function depends on coordinated communication amongst the 
hypothalamus, pituitary and gonads (ovaries in females and testes in males). The 
hypothalamus synthesizes and releases gonadotropin-releasing hormone (GnRH), which is 
transported in hypothalamic-pituitary portal vessels to the anterior pituitary gland where it 
binds to GnRH receptors (GnRHR) on gonadotrope cells. This GnRH-GnRHR interaction 
stimulates the production of second messenger, inositol-1,4,5-triphosphate (IP3), leading to 
synthesis and release of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH), which act on the gonads to initiate gametogenesis. Primary sexual 
characteristics are established during gestation according to the genotype of an individual. A 
46XX genotype results in a female phenotype, while a 46XY genotype results in a male 
phenotype. The ‘Y’ chromosome carries essential genes for male anatomical development, 
which are absent in females. Male and female gonadal function is regulated hormonally in a 
sex-specific manner throughout an individual’s lifetime, commencing during gestation (Levy, 
Berne, Koeppen, 2005).  
During embryonic development, GnRH neurons originate with olfactory neurons in 
the olfactory placode (6 weeks gestation). GnRH neurons then migrate to- and mature in the 
hypothalamus (González-Martínez et al., 2004). Failure of this neuronal migration can arise 
from mutations of the Kallmann syndrome 1 (KAL-1) and fibroblast growth factor receptor 1 
(FGFR1) genes, which encode proteins that direct migration of GnRH neurons to the 
hypothalamus and olfactory neurons to the nasal epithelia (González-Martínez et al., 2004). 
Incorrect localization of the olfactory cells causes anosmia, while failure of the GnRH 
neurons to reach the hypothalamus causes infertility by disrupting GnRH secretion. 
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Individuals that possess both of these abnormal phenotypes are diagnosed with the 
Kallmann’s syndrome form of hypogonadotropic hypogonadism (HH) (González-Martínez et 
al., 2004). 
GnRH production varies during the different stages of human life. Since peripheral 
GnRH concentrations are very low (too low to measure), circulating gonadotropin 
concentrations are considered to reflect GnRH production levels and GnRH concentrations in 
the pituitary. LH and FSH concentrations are low in infancy and suppressed during childhood, 
which are the non-reproductive years of human life. Gonadotropin concentrations increase at 
puberty and are maintained through the reproductive years (Levy, Berne & Koeppen, 2005). 
Follicles of the female ovary and seminiferous tubules of the male testis are sites for 
the development of gametes. The gonads contain endocrine cells (granulosa and theca cells in 
ovaries and Sertoli and Leydig cells in testes) that secrete sex steroid hormones (androgens 
and oestrogens), which promote gametogenesis. The sex steroids also stimulate development 
of secondary sexual characteristics at puberty. Puberty is the start of the reproductive stage of 
life initiated by an increase in GnRH production. This GnRH increase is believed to be due to 
disinhibition of an upstream regulator of GnRH secretion. Upstream regulators of GnRH 
include neuropeptide ligands, such as kisspeptin and neurokinin B, which activate receptors 
on the GnRH-producing neurons (Silveira et al., 2010; Ohkura et al., 2009). Kisspeptin has 
been identified as a potent stimulator of gonadotropin secretion, especially LH, by regulating 
its stimulation of GnRH release. Neurokinin B has been identified as having an important role 
in the reproductive axis at the level of GnRH secretion (Silveira et al., 2010; Navarro, 2013). 
The pubertal GnRH surge is responsible for the accompanying increase in gonadotropin 
levels. The gonadotropin increase promotes a testosterone increase in males causing the testes 
to enlarge and begin producing sperm for the first time. In females, GnRH stimulates cyclical 
release of LH and FSH, which results in active ovarian cycles that begin at puberty and 
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continue until menopause. Menopause occurs when the ovarian follicles are depleted and the 
ovaries no longer produce gonadal steroids. Lack of gonadal steroids causes reproductive 
function to cease in menopausal females. LH primarily stimulates production of androgens by 
theca and Leydig cells. FSH stimulates production of estrogens, mainly estradiol, by 
granulosa cells in females. In males, FSH acts on Sertoli cells in the seminiferous tubules to 
stimulate spermatogenesis. Gonadal steroids are responsible for the secondary sexual 
characteristics that develop at puberty. Distinguishing secondary sexual characteristics in 
males include deepening of the voice, broadening of shoulders and male pattern hair growth 
pattern on the face, chest and body. Female secondary sexual characteristics include breast 
development, widening of the hips and absence of hair growth on the face and chest (Levy, 
Berne, Koeppen, 2005). 
An initial increase in oestrogen concentrations secreted by maturing ovarian follicles 
during the first 2 weeks of the female menstrual cycle causes thickening of the endometrium. 
Oestrogen from the follicles also causes an increase in GnRH and GnRH pulse frequency 
which stimulates a surge in LH concentrations. The LH surge causes a mature follicle to 
rupture and release an ovum into the fallopian tube. This ovum is then ready to be fertilized 
by male sperm to form an embryo. The ruptured ovarian follicle develops into a corpus 
luteum, which produces oestrogen and progesterone. If fertilization does not occur, the corpus 
luteum degenerates causing a decrease in oestrogen and progesterone levels, which results in 
breakdown of the endometrial lining and menstrual bleeding. However, should fertilization 
and implantation occur, the chorionic membrane between the mother and her developing 
foetus produces human chorionic gonadotropin (hCG). hCG is a heterodimeric protein with 
an α subunit identical to those of LH and FSH and a β subunit that is 80% identical to that of 
LH (Stenman & Alfthan, 2013). Owing to this structural similarity, LH and hCG interact with 
the same receptor, the LH/CG receptor (Choi & Smitz, 2014b). hCG prevents degeneration of 
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the corpus luteum during the first trimester of pregnancy and stimulates production of 
estrogen and progesterone. hCG production increases until the placenta is fully developed and 
can support growth of the foetus during the remaining term of pregnancy. The homology of 
LH and hCG allows for a functional substitution during the different life stages. In addition to 
stimulating ovarian steroid production, hCG also regulates foetal development. In the male 
foetus, placental hCG acts on the foetal testes to stimulate production of testosterone in the 
environment of low maternal and foetal LH. This early hCG-stimulated testosterone exposure 
stimulates development of male anatomy in the foetus (Choi & Smitz, 2014a). In contrast, LH 
and FSH are required for sexual development at puberty and a deficiency results in decreased 
production of gonadal steroids and decreased gonadal growth that results in delayed or absent 
puberty. Individuals that have delayed pubertal development and infertility caused by low 
levels of gonadotropins are diagnosed with HH (Choi & Smitz, 2014a).  
1.2.  Etiology of hypogonadotropic hypogonadism  
As mentioned earlier, failed migration of GnRH neurons to the hypothalamus causes 
infertility by disrupting GnRH production. Reduced or absent GnRH secretion results in 
decreased levels of LH and FSH that causes the Kallmann’s syndrome form of HH (Fraietta et 
al., 2013). HH can also occur without anosmia and is known as normosmic HH, which has a 
variety of etiologies that manifest variable clinical features, ranging from partial to complete 
forms of the hypogonadism (Fraietta et al., 2013). 
HH can arise from mutations of the GnRH gene that result in aberrant peptide that 
cannot activate its receptor, disrupting stimulation of LH and FSH release (Maione et al., 
2013; Bouligand et al., 2009). Disruption of gonadotropin secretion results from mutations of 
the genes for GnRH regulators, such as kisspeptin and neurokinin B, or their receptors 
(Navarro, 2013). However, population studies have shown that mutations of the GnRHR gene 
are the most common cause of HH (Francou et al., 2016). These mutations partially or 
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completely disrupt the ability of GnRH to stimulate gonadotropin production (Kottler et al., 
1999).  
1.3. GnRHR mutations that cause HH 
Mutations of the GnRHR potentially impact receptor function via reduced binding 
affinity for GnRH, decreased signalling in response to GnRH binding or decreased expression 
of the receptor protein on the gonadotrope cell surface (Kottler et al., 1999; Tello et al., 
2012). Owing to the recessive inheritance of HH, causal mutations tend to go undetected in 
asymptomatic carriers and only manifest a diseased state in homozygous individuals and in 
compound heterozygotes (Francou et al., 2016). A number of HH cases are sporadic forms, 
arising from de novo mutations of the GnRHR gene (Fraietta et al., 2013). 
The first description of a HH-causing mutation of the human GnRHR was the 
Glu
2.53(90)
Lys (for explanation of numbering scheme, please see section 1.6) missense 
mutation. This involves substitution of the glutamic acid residue at position 2.53(90) (refer to 
page 11 for residue numbering scheme) of the GnRHR protein with lysine. The mutation 
causes a complete HH phenotype in homozygous carriers (Söderlund et al., 2001). To date, 26 
naturally-occurring mutations that cause HH have been identified in the human GnRHR gene 
(Table 1.1) (Seminara et al., 1998; Tello et al., 2012). In vitro analysis has shown that most of 
these mutations disrupt expression of the GnRHR protein and some disrupt receptor function 
(Table 1.1). 
In vitro studies, in which the Glu
2.53(90)
Lys mutant GnRHRs expressed in COS7 cells, 
showed no measurable binding of GnRH and no measurable GnRH-stimulated inositol 
phosphate (IP) production (Leanos-Miranda, 2002; Tello et al., 2012). Small membrane-
permeable GnRH antagonist molecules, referred to as pharmacological chaperones, enhance 
the cell surface expression of misfolded and poorly expressed mutant receptor proteins by 
acting as scaffolds to stabilize and correct their folding (Ulloa-Aguirre et al., 2014). 
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Depending on the GnRHR mutation (see table 1.1), this resultant enhanced expression 
sometimes leads to restoration of mutant receptor expression, with function that is similar to 
wild type, as is the case for the Glu
2.53(90)
Lys mutant GnRHR (Ulloa-Aguirre et al., 2014).  
Confocal microscopy of fluorescently labelled GnRHR showed that prior to 
pharmacological chaperone treatment, the Glu
2.53(90)
Lys mutant protein was retained in the 
endoplasmic reticulum (ER) and was not expressed on the plasma membrane. In contrast, the 
wild type GnRHR was localized both on the plasma membrane and intracellularly (Brothers et 
al., 2004). This suggests that the Glu
2.53(90)
Lys mutation disrupts GnRHR trafficking to the 
cell membrane. Thus, poor expression of GnRHR protein in vivo is the likely cause of HH in 
patients who are homozygous for the Glu
2.53(90)
Lys GnRHR mutation. It has not been 
established how the Glu
2.53(90)
Lys mutation disrupts the structure of the GnRHR at the 
molecular level that results in this decreased expression. Therefore, the aim of this study is to 
determine the role of the Glu
2.53(90)
 residue in the expression and function of the GnRHR. 
1.4. Protein biosynthesis and the quality control system  
Biosynthesis of membrane proteins occurs in the ER. This involves targeting to- and 
insertion into- the ER membrane, which stabilizes correct folding of the membrane-spanning 
segments (Schlinkmann et al., 2012). To obtain its functional state, a protein must transition 
from unfolded to folded by crossing a free-energy barrier to reach its most energetically stable 
free-energy conformation (Chung et al., 2015; Herczenik & Gebbink 2008). Owing to the 
complexity of this process, protein translation and assembly is error-prone (Hebert & 
Molinari 2007; Broadley & Hartl 2009). Therefore, the ER has a quality control system 
(QCS), comprised of endogenous chaperone proteins that recognize misfolded nascent 
proteins and correct their folding. This enhances membrane protein assembly and improves 
transport of the correctly folded protein to the plasma membrane. A combination of defects in 
protein structure, including exposed, rather than buried, hydrophobic amino acid side-chains, 
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incorrect salt-bridge formation or incomplete disulfide or hydrogen bonds, contributes to the 
protein being recognized as misfolded by the QCS (Araki & Nagata, 2011; Chung et al, 
2015). Variations in amino acid composition that result from mutations of the gene encoding 
a protein may destabilize protein folding (Herczenik & Gebbink 2008). If the QCS 
chaperones cannot correct folding of the mutant protein, the misfolded protein is not delivered 
to the plasma membrane and it is usually ubiquitin-tagged and targeted to proteasome 
complexes for degradation (Tan et al., 2004; Alfredo Ulloa-Aguirre et al., 2004; Conn & 
Janovick, 2009).  
Degradation of misfolded and unfolded proteins prevents continuous unsuccessful 
attempts of the chaperones to correctly fold ‘un-rescuable’ proteins and is essential to 
maintain protein homeostasis within the cell (Broadley & Hartl, 2009; Araki & Nagata, 2011). 
The intracellular accumulation of misfolded and/or unfolded proteins has been recognized as 
the cause of diseases including Alzheimer’s, Parkinson’s and Huntington’s diseases, type 2 
diabetes and retinitis pigmentosa (Hartong et al., 2006; Herczenik & Gebbink, 2008; 
Reynaud, 2010). The aggregates formed by misfolded proteins that are responsible for these 
and other diseases, disrupt normal functioning of the cell within which they accumulate. 
Disruption of cellular function results from toxicity induced by increases in oxidative stress, 
ER stress and malfunction, increased membrane permeability, altered calcium concentrations, 
malfunctioning mitochondria and/or eventual stimulation of apoptosis leading to untimely cell 
death (Herczenik & Gebbink, 2008; Reynaud, 2010). 
1.5. Rescue of misfolded mutant GnRHRs  
Of the 26 known HH-causing mutant GnRHRs that were transfected into cells, 20 
showed little to no GnRH-stimulated IP production or binding of GnRH (table 1.1). 
Treatment of these cells with membrane-permeable small molecule GnRHR ligands resulted 
in measurable GnRHR expression and function in vitro. The small molecule GnRHR 
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antagonists act as artificial targeted protein folding chaperones, which are thought to stabilize 
intramolecular interactions within the mutant protein that may allow correct folding. The 
correctly folded proteins are then trafficked to- and expressed on the cell surface. This 
suggests that 20 of the 26 characterized HH-causing mutations of the GnRHR disrupt protein 
folding. 
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Table 1.1: Effect of HH-associated GnRHR gene mutations. The effects of GnRHR gene mutations on disease severity and on in vitro GnRHR expression and function are 
summarised. 
Mutation HH severity Expression
a
 Ligand Binding Rescue?
 b
 Signalling Reference 
Ala
129
Asp in TM3 Complete NR
d
 No binding NR None (Caron et al. 1999) 
Asn
10
Lys,Gln
11
Lys in 
amino terminal 
Partial Normal ↓ c affinity NR ↓ (Costa et al. 2001; Beneduzzi et al. 2012) 
Thr
32
Ile in TM1 Complete ↓ ↓affinity Yes ↓ (Bédécarrats et al. 2003) 
Glu
90
Lys in TM2 Complete ↓ No binding Yes None (Söderlund et al. 2001; Tello et al. 2012) 
Thr
104
Ile in ECL1 Complete ↓ ↓affinity Yes ↓ (Maya-Núñez et al. 2011) 
Gln
106
Arg in ECL1 Partial Normal ↓ NR ↓ (Costa et al. 2001) 
Tyr
108
Cys in ECL1 Complete ↓ No binding Yes None (Maya-Núñez et al. 2011) 
Arg
139
His in TM3 and 
ICL2 
Complete Normal No binding Yes None (Ballesteros et al. 1998) 
Arg
139
Cys in TM3 and 
ICL2  
Complete ↓ Unchanged affinity Yes ↓ (Topaloglu et al. 2006) 
Pro
146
Ser in ICL2 Partial NR NR NR ↓ (Vagenakis et al. 2005) 
Ser
168
Arg in TM4 Complete Normal No binding NR None (Pralong et al. 1999) 
Ala
171
Thr in TM4 Complete Normal No binding NR None (Beate Karges et al. 2003) 
Cys
200
Tyr in ECL2 Partial ↓ ↓affinity Yes ↓ (Bédécarrats et al. 2003) 
Ser
217
Arg in TM5 Variable NR ↓affinity NR ↓ (de Roux et al. 1999) 
Arg
262
Gln in ICL3 Partial ↓ Unchanged affinity NR ↓ (de Roux et al. 1997) 
Leu
266
Arg in ECL3 Complete NR No binding Yes None (Bédécarrats et al. 2003) 
Cys
279
Tyr in TM6 Complete NR No binding Yes None (Bédécarrats et al. 2003) 
Pro
282
Arg in TM6 Complete ↓ No binding No None (Tello et al. 2012) 
Tyr
283
His in TM6 Complete NR NR NR NR (Beneduzzi et al. 2012) 
Tyr
284
Cys in TM6 Complete NR ↓affinity Yes ↓ (Layman et al. 1998) 
Leu
314
X in TM7 Complete NR No binding No None (Kottler et al. 1999) 
Pro
320
Leu in TM7 Complete Normal No binding NR None (Meysing et al. 2004) 
Tyr
323
Cys in TM7 Partial ↓ Unchanged affinity Yes ↓ (Tello et al. 2012) 
Exon 2 deletion Complete None No binding No None (Silveira et al. 2002) 
a
 Expression addresses detection of mutant GnRHR on the cell surface 
b
 Rescue refers to increased expression of poorly expressed mutants following treatment with pharmacological agents in vitro 
c 
Decreased compared with wildtype 
d 
NR, Not reported 
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When cells transfected with the Glu
2.53(90)
Lys mutant GnRHR were treated with the 
small molecule antagonists IN3 or NBI-42902, the mutant receptor subsequently showed 
GnRH binding and second messenger responses to GnRH stimulation similar to the wild type 
receptor (Brothers et al., 2004; Leanos-Miranda, 2002; Tello et al., 2012). The rescued 
function of the Glu
2.53(90)
Lys mutant GnRHR expression suggests that this mutation causes 
misfolding of the GnRHR, but has no other effect on the molecular function. 
Other forms of in vitro ‘rescue’ for the poorly expressed mutant GnRHRs involve 
genetic modification, including the addition of a carboxy-terminal tail. It has been shown that 
expression of the human GnRHR is enhanced by addition of the carboxy-terminal tail of a 
catfish GnRHR (Lin et al., 1998; Janovick et al., 2003). The Glu
2.53(90)
Lys mutant GnRHR 
with the catfish carboxy-terminal tail showed enhanced expression, which was accompanied 
by GnRH-stimulated IP production similar to wild type levels, indicative of rescued function 
(Janovick et al., 2003). Appending the carboxy-terminal tail of the human type II GnRHR to 
the human GnRHR enhanced expression of other poorly expressed mutant GnRHRs 
(Flanagan et al., 2000). Expression of the wild type GnRHR showed a similar increase when a 
carboxy-terminal tail was appended. This suggests that these receptors are not maximally 
expressed and may be partially misfolded even in the absence of mutations (Janovick et al., 
2003).  
1.6. G protein-coupled receptors: Homology 
The GnRHR belongs to the large family of G protein-coupled receptors (GPCRs) 
(Millar et al., 2004). GPCRs are integral membrane proteins that transmit extracellular 
signals, conveyed by diverse ligands, across a cellular membrane to activate cytosolic G 
proteins (Naor, 2009). These extracellular signals encompass a vast array of stimuli, including 
light, ions, odours, hormones, neurotransmitters, drugs and cytokines (Gether & Kobilka, 
1998; Pardo et al., 2007). GPCRs are integral to many physiological systems and are 
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therefore involved in the pathophysiology of many diseases, making them important targets 
for therapeutic intervention (Tehan et al., 2014). The tertiary structure of the GnRHR has not 
been elucidated and it has been possible to obtain crystal structures of only a small, but 
growing, number of related GPCRs (Standfuss et al., 2011; Rasmussen et al., 2011; Cherezov 
et al., 2007; Deupi et al., 2012). Therefore, much of what is known about the GnRHR 
structure has been inferred from molecular models based on available GPCR structures 
(Söderhäll et al., 2005; Mayevu et al., 2015). The GnRHR exhibits characteristic features of 
GPCRs, including seven membrane-spanning segments, which form a bundle of α-helices 
relatively perpendicular to the plane of the membrane. The membrane-spanning segments are 
connected by three intracellular loops (ICL) and three extracellular loops (ECL). The 
membrane-spanning segments are amphipathic with amino acid residues that face the 
membrane lipids being hydrophobic, whereas the side chains of residues oriented towards the 
interior of the helical bundle are largely hydrophilic. The extracellular region, which is 
variable among different GPCRs, is primarily responsible for ligand recognition. The 
transmembrane helix bundle forms the structural core, which conveys the ligand binding 
message to the cytosolic surface of the receptor that interacts with cytosolic proteins, 
including G proteins (Forfar & Lu, 2011). The mammalian GnRHR also has a unique feature, 
when compared with most other GPCRs, in that it lacks an intracellular carboxy-terminal tail 
(Thompson & Kaiser, 2014), although the tail is present in non-mammalian and type II 
GnRHRs (Lin et al., 1998). A second form of GnRH, GnRH II, is present in a number of 
species ranging from amphibians to humans. The type II GnRHRs are the cognate receptors 
for GnRH II, and have carboxyl-terminal tails (Millar et al., 2001). In humans, the type II 
GnRHR has a stop codon within its coding sequence, which results in a truncated receptor 
protein. If this truncated receptor is expressed, its function has not been defined (Millar, 
2003). 
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Sequence alignment of GPCRs led to the observation of highly conserved residues and 
amino acid motifs within the seven transmembrane (TM) segments, from which different 
GPCR classes were identified (Baldwin, 1993). GPCRs are divided into five different classes, 
A, B, C, F and O, based on sequence similarities. The GnRHR has the conserved sequences 
and motifs that are characteristic of class A, which includes the most widely studied GPCRs, 
rhodopsin and the β2-adrenergic receptor (Isberg et al., 2015). Class B includes secretin and 
adhesion receptors, class C includes glutamate and taste I receptors, while classes F and O 
include Frizzled receptors and taste II receptors respectively (Isberg et al., 2015). Since the 
different class A GPCRs vary in the lengths of the extracellular and intracellular loops, 
Ballesteros and Weinstein proposed a universal numbering system for amino acids of 
different class A GPCRs. The most conserved residue in each TM is assigned the arbitrary 
reference number 50, preceded by the TM number. Residues in each TM are numbered 
relative to the most conserved residue, with the sequence number of the residue in the 
receptor in parenthesis (Ballesteros & Weinstein, 1995). Thus, the Glu
90
 residue of the 
GnRHR is designated Glu
2.53(90) 
because it is located three residues past the location of the 
most conserved residue of TMD2, Asn
2.50(87)
. Similarly, the Trp
280
 residue of the GnRHR is 
designated Trp
6.48(280)
 because it is located two residues before the most conserved residue of 
TM6, Pro
6.50(282)
. This consensus numbering scheme allows the comparison of equivalent TM 
amino acids in different rhodopsin-like GPCRs, facilitating extrapolation of the role of a 
particular residue from one GPCR to another (Van Rhee et al., 2011). Figure 1 depicts a 
schematic of the GnRHR sequence showing the positions of the most conserved residues in 
GPCRs and the positions of the Glu
2.53(90)  
and Trp
6.48(280)
 residues.  
The sequences of class A GPCRs show highly conserved amino acid motifs, 
conserved residues that are found grouped together, within TM domains. Three key motifs of 
class A GPCRs are the Asp/Glu
3.49
-Arg
3.50
-Tyr
3.51
 ((D/E)RY)
 
motif at the cytosolic end of 
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TM3, the Cys
6.47
-Trp
6.48
-x
6.49
-Pro
6.50
-Tyr
6.51
 (CWxPY)
 
motif in TM6 and the Asn
7.49
-Pro
7.50
-
x
7.51
-x
7.52
-Tyr
7.53
 (NPxxY)
 
motif in TM7 where ‘x’ is any amino acid (Palczewski, 2006; 
Smith, 2010; Vohra et al., 2013). It has been proposed that the highly conserved amino acids 
of class A GPCRs are the key to mediating the conserved GPCR function by facilitating 
similar changes in protein conformation that constitute receptor activation in response to 
agonist binding (Dalton et al., 2015). Comparison of the crystal structures of inactive and 
active GPCRs suggests that the residues of conserved motifs have conserved roles in the 
rearrangements of TMs 3, 5, 6 and 7 that occur during GPCR activation (Angel et al., 2009; 
Miura et al., 2003; Tehan et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic two-dimensional representation of the human GnRH receptor structure. The seven 
TM segments are connected by three intracellular and three extracellular loops (red). The amino terminus is 
shown on the extracellular side of the membrane but the GnRHR lacks a carboxy-terminal tail at its intracellular 
end (red). Squares in blue represent the most highly conserved residues of each TM helix, bold numbers 1-7 
indicate the helices/TM segments. The circles in yellow indicate the locations of Glu
2.53(90) 
and Trp
6.48(280) 
residues. 
 
1.7. G protein-coupled receptors: Theoretical models of receptor activation 
A GPCR that is bound by an agonist changes conformation within the cell membrane 
and subsequently activates membrane-associated cytosolic proteins, particularly G proteins, 
Intracellular 
Extracellular 
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which induce intracellular signalling. An agonist binds to a receptor and initiates a 
physiologic response by stabilizing the receptor in an active conformation. An antagonist will 
prevent the physiologic response by binding to a receptor and preventing an agonist from 
activating the receptor. Models of receptor activation evolved from the simple notion of a lock 
and key mechanism to more complex concepts with added mathematical variables (Kenakin, 
2009). Pharmacological studies of drug and receptor interactions led to the two-state or binary 
receptor model, which proposes that a GPCR exists in equilibrium between one of two 
functional states or conformations; active (R*) or inactive (R) (Gether & Kobilka, 1998; 
Khilnani & Khilnani, 2011). A GPCR is activated by binding of an agonist that induces a 
conformational change of the receptor stabilizing the R* or active conformation, which binds 
to G protein. In contrast, a GPCR is inactivated by binding of an antagonist, which prevents 
agonist binding, receptor activation and coupling to G protein. This model evolved into the 
extended ternary complex model to accommodate the discovery that some GPCRs, including 
adrenergic and opioid receptors, may induce a signalling response in the absence of an 
agonist. This spontaneous mode of GPCR activation and coupling to G protein is known as 
constitutive activity. Ligands that are able to bind to, and cause a GPCR to transition from 
active to inactive, are known as inverse agonists. Inverse agonists decrease constitutive 
activity of a receptor by stabilizing it in the inactive conformation despite the GPCR being 
coupled to a G protein (Kenakin, 2009; Khilnani & Khilnani, 2011). Evidence that certain 
agonists and inverse agonists can partially activate or partially inactivate a GPCR led to the 
idea that receptors exist in multiple states, whereby a single GPCR can have a collection of 
conformations. Each of these conformations interacts with a ligand in a different way, giving 
rise to different possibilities of signalling responses for a single GPCR (Kenakin, 2009). 
Mutations may stabilize inactive receptor conformations, preventing the R to R* transition 
thereby maintaining the inactive state. Some receptor mutations stabilize the R* conformation 
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causing constitutive activity. Most mutations of the GnRHR do not result in constitutive 
activity, but there has been a single report of constitutive activity in a highly modified form of 
the Glu
2.53(90)
Lys mutant GnRHR in ECL2 (Janovick et al., 2011). 
1.8. G protein-coupled receptors: Function 
The physiological function of all GPCRs involves transmission of extracellular 
signals, particularly agonist binding, across a cellular membrane to activate various 
intracellular signalling pathways (Naor, 2009). Models of GPCR activation imply that agonist 
binding is associated with a conformational change of the transmembrane helical bundle that 
stabilizes the active state(s), which activates cytosolic G proteins. Structural rearrangements 
of the membrane-spanning segments arise from rearrangement of intramolecular interactions 
within individual TM segments and between different TM segments (Gether & Kobilka, 
1998). It is assumed that because the GnRHR has the highly conserved residues characteristic 
of class A GPCRs, it undergoes movements that are similar to those of other class A GPCRs 
(Mayevu et al., 2015). 
G proteins are heterotrimeric membrane-associated proteins, consisting of Gα, β and γ 
subunits. This family of evolutionarily conserved proteins controls the onset of many of the 
intracellular signalling pathways that mediate GPCR functions. G proteins exist in an inactive 
state, which is characterised by the Gα subunit of the heterotrimer being bound to guanosine 
diphosphate (GDP). G protein activation is initiated by release of GDP and binding of 
guanosine triphosphate (GTP) to the Gα subunit. Following binding of GTP to Gα, the Gβγ 
dimer dissociates and the separated subunits interact with effector proteins (Milligan & 
Kostenis, 2009; Johnston & Siderovski, 2007). The Gα-GTP subunit and the Gβγ dimer each 
modulate downstream effectors, including nucleotide cyclases, ion channels and 
phospholipases. This regulates production of second messengers, such as cyclic AMP 
(cAMP), IP3 and diacylglycerol (DAG), which initiate cellular signalling pathways that 
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translate the external stimulus to a physiological response (Naor, 2012). G proteins have been 
classified into four subfamilies; Gαs, Gαi/o, Gαq/11 and Gα12/13, based on sequence 
homology of α subunits that activate distinct signalling pathways. Gαs activates adenylyl 
cyclase, which catalyses cAMP production; Gαi/o inhibits adenylyl cyclase activity and Gα12/13 
activates small GTPases involved in cell migration. The GnRHR couples to the Gαq/11 family 
of G proteins, which activates phospholipase Cβ (PLCβ). PLCβ catalyses the production of 
second messengers, IP3 and DAG, from the membrane phospholipid, phosphatidylinositol 
bisphosphate (PIP2). IP3 stimulates mobilization of Ca
2+
 ions from the ER. DAG and 
cytosolic Ca
2+
 activate protein kinase C (PKC). PKC then activates mitogen-activated protein 
kinase (MAPK) (Naor & Huhtaniemi, 2012; Naor, 2009; Grosse et al., 2000), which, in turn, 
regulates gonadotropin production and secretion. 
1.9. G protein-coupled receptors: Crystal structures 
Obtaining tertiary structures of GPCR proteins is difficult. As GPCRs are integral 
membrane proteins, they become unstable when removed from their natural membrane 
environment to be crystallized. GPCRs are often poorly expressed, with their low abundance 
making it difficult to obtain enough protein to generate crystals. Receptor proteins are 
naturally flexible and exist in multiple conformations. Therefore, another challenge is to 
obtain a single conformation from the numerous conformations that individual protein 
molecules assume in order to successfully generate a single static crystal structure (Carpenter 
et al., 2008; Ghosh et al. 2015). Because of these difficulties, crystal structures of only a small 
number of different GPCRs have been determined. Rhodopsin and the β-adrenergic receptors 
are the most widely studied and understood of the class A GPCRs. This detailed knowledge 
has allowed crystallization of these receptors in both inactive and active states (Standfuss et 
al., 2011; Rasmussen et al., 2011; Cherezov et al., 2007; Deupi et al., 2012). More recently, 
advances in crystallographic technology and strategies to overcome the technical challenges 
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have led to an increase in the number of different GPCRs that have been crystalized 
(Carpenter et al., 2008; Ghosh et al., 2015). Since there is no available crystal structure of the 
GnRHR, I provide a detailed review of crystal structures of other class A GPCRs to assess the 
functions of residues in position 2.53 in order to better understand how the Glu
2.53(90)
Lys 
mutation disrupts GnRHR function. In particular, the earlier rhodopsin and β2-adrenergic 
receptor crystals and some of the more recent structures such as the neurotensin receptor 
(NT1R) have been used as homology models for GnRHR structure (Mayevu et al., 2015). The 
information gained from probing GPCR crystal structures has given insight into areas of 
GPCR research that were previously lacking, including the nature of receptor interactions 
with ligands and G proteins at the structural level, whereas comparison of inactive and active 
receptor structures has improved the understanding of receptor activation mechanisms (Deupi, 
2014; Rasmussen et al., 2011).  
1.10. Crystal structures of inactive rhodopsin  
1.10.1. Overall fold and proline kinks 
The first GPCR crystal structure to be determined was a low resolution structure of the 
inactive conformation, or dark-state, of rhodopsin, consisting of the apoprotein, opsin, 
covalently bound to 11-cis-retinal, which acts as an inverse agonist (Palczewski et al., 2000). 
This crystal structure confirmed predictions from sequence analyses that GPCRs would have 
seven membrane-spanning α-helical segments with an extracellular NH2-terminus and an 
intracellular COOH-terminal tail. Positions of the highly conserved residues of each 
membrane-spanning segment, as well as the highly conserved structural motifs within these 
TMs were also defined. The proline residues, Pro
5.50
, Pro
6.50
 and Pro
7.50
, which are highly 
conserved in TMs 5, 6 and 7 of class A GPCRs were found to cause structural distortions in 
the α-helices in the form of bends or kinks, but these are not classical proline kinks. For 
example, Pro
6.50(267)
 of the CWxPY motif in TM6, was shown to have a more exaggerated 
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bend angle than a standard proline-kink and it was hypothesized that a change in this bend 
angle would be involved in receptor activation (Palczewski et al., 2000; Trzaskowski et al., 
2012). To achieve this bend angle, Pro
6.50(267) 
is stabilized by an interaction with a water 
molecule, which makes hydrogen bonds to Cys
6.47(264)
, Tyr
6.51(268)
 of the CWxPY motif and 
Pro
7.38(291) 
(Standfuss et al., 2011). The overall GPCR fold is stabilized by interactions 
involving non-covalent intrahelical and interhelical interactions (Venkatakrishnan et al., 
2013). Some of the hydrogen bond interactions are mediated by water molecules, which form 
a network of hydrophilic interactions (Pardo et al., 2007; Angel et al., 2009). 
1.10.2. Water-mediated hydrogen bond networks and the CWxPY motif 
The most highly conserved residues within inactive rhodopsin crystals are connected 
by hydrogen bonds with nearby water molecules. It is believed that these water molecules 
mediate long distance hydrogen bond interactions between residues of different helices that 
are too far apart to make direct interactions. For example the Trp
6.48(265)
 residue of the 
CWxPY motif in TM6 is connected to Asp
2.50(83)
,
 
the most conserved residue of TM2, as well 
as to Asn
7.49(302)
 of the NPxxY motif and Ser
7.45(298)
 in TM7 (Li et al., 2004; Standfuss et al., 
2011). An interaction between the TM2 Asp
2.50 
and TM7 Asn
7.49
 residue had been predicted, 
based on the reciprocal interchange of Asp
2.50 
and Asn
7.49 
to Asn
2.50 
and Asp
7.49 
in the GnRHR, 
when compared with other class A GPCRs (Zhou et al., 1994; Flanagan et al., 1999). The 
rhodopsin crystal structures showed that this interaction could not be direct owing to the 
distance between the Asp
2.50 
and Asn
7.49
 residues. However, an indirect interaction via 
hydrogen bonding to water molecules was noted (Palczewski et al., 2000). The inactive 
rhodopsin crystals show a hydrophobic barrier located on the cytosolic side Asp
2.50(83) 
that 
comprises six residues of TMs 2, 3 and 6 including, Leu
2.43(76)
, Leu
2.46(79)
, Leu
3.43(128)
, 
Leu
3.46(131)
, Met
6.36(253) 
and Met
6.40(257)
. The barrier separates the ligand binding pocket from 
the cytoplasmic G protein binding site, which is occluded and inaccessible in the inactive state 
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(Standfuss et al., 2011). Met
2.53(86) 
was proposed to interact with Trp
6.48(265) 
of rhodopsin to 
separate the water networks at the extracellular and intracellular sides (Deupi et al., 2012). 
1.10.3. Ligand binding pocket 
All seven TM segments and a region of the extracellular part of rhodopsin contribute 
to binding of cis-retinal in the inactive state (Menon et al., 2001). Retinal is covalently linked 
to the positively charged Lys
7.43(296)
, which is stabilized by the negatively charged counterion 
Glu
3.28(113) 
via a salt-bridge interaction. The binding pocket itself places retinal between the 
TMs and means that it is buried by side-chains of surrounding TMs (Palczewski et al., 2000; 
Teller et al., 2001). Overall, about 22 residues are located close enough to interact with retinal 
and form the ligand binding pocket of inactive rhodopsin (Li et al., 2004). Of these residues, 
Trp
6.48(265) 
of the CWxPY motif
 
was found to make hydrophobic contact with carbon 18 (C18) 
of the β-ionone ring of 11-cis-retinal (Li et al., 2004). Several other residues make 
hydrophobic contacts with the ligand including Met
5.42(207)
, Phe
4.47(212)
 and Tyr
6.51(268)
. 
However, far fewer residues contact the ligand by polar interactions (Li et al., 2004). There 
was no mention of a direct interaction of retinal with the Met
2.53(86)
 residue of inactive 
rhodopsin. (Li et al., 2004; Venkatakrishnan et al., 2013). 
1.10.4. Ionic-lock 
The inactive rhodopsin crystal showed that the Arg
3.50(135) 
of the conserved (D/E)RY 
motif at the cytosolic end of TM3 formed a salt-bridge with the adjacent Glu
3.49(134)
 of the 
(D/E)RY motif and formed an interhelical salt-bridge with Glu
6.30(247) 
at the cytosolic end of 
TM6 (Palczewski et al., 2000). This interaction linking TMs 3 and 6 is known as the ionic-
lock, which had been predicted to stabilize inactive GPCR conformations (Vogel et al., 2008). 
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1.10.5. Location of residues 5.58 and 7.53 
Tyr
7.53(306) 
of the NPxxY motif is constrained in the inactive rhodopsin crystal by an 
aromatic interaction with the Phe
7.60(313) 
residue of TM8, placing it away from the TM core 
bundle and toward TM1 (Goncalves et al., 2010; Deupi et al., 2012). It is believed that this 
constraining interaction is one that stabilizes the inactive state of rhodopsin (Trzaskowski et 
al., 2012; Goncalves et al., 2010). Like Tyr
7.53(306)
, another highly conserved residue in TM5, 
Tyr
5.58(223) 
is also positioned facing away from the TM core bundle in the inactive rhodopsin 
crystal (Goncalves et al., 2010). 
1.11. Crystal structures of rhodopsin-like GPCRs in inactive conformations 
The first crystal structures of class A GPCRs other than rhodopsin, referred to here as 
‘rhodopsin-like’ GPCRs, were crystallized long after the initial rhodopsin crystal owing to 
technical difficulties that required multiple methodological innovations in crystallography 
(Ghosh et al., 2015). The main difficulties are the flexibility and instability of receptor 
proteins. There are three types of receptor flexibility, the first arising simply from ‘loose ends’ 
such as amino and carboxy termini and long ECLs within the 7TM structure. Technical 
innovations to overcome some of the problems associated with protein flexibility involved 
subjecting the receptor itself to recombinant technologies such as the truncation of ‘loose ends 
or loops’ and/or incorporation of stabilizing proteins, including the T4 lysozyme in ICL3 to 
form a fusion protein. The T4 lysozyme is a stable and water-soluble protein. Inserted 
proteins allow for hydrophilic contacts that aid in crystallography (Zhou et al., 2012). A 
second type of flexibility is the conformational flexibility of the TM bundle itself that requires 
the introduction of thermostabilizing mutations to achieve the stability needed for 
crystallography. Many thermostabilizing mutations are known to affect receptor function and 
may thus cause artefacts in crystal structures (Ghosh et al., 2015).  
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A third type of flexibility arises from spontaneous conformational interchanges of the 
protein. Since unliganded GPCR proteins exist in equilibria of active and inactive 
conformations, co-crystallization of receptors with ligands was needed to stabilize either 
active or inactive receptor conformations. Such ligands may dissociate from the receptor and 
allow changes in conformation that again induce flexibility that hinders crystal formation. 
Development of covalently bound or slowly diffusing, high affinity full inverse agonists was 
needed to overcome this problem (Ghosh et al., 2015). Nevertheless many of these ligands do 
not fully stabilize the receptor in a fully inactive state and crystal structures may represent a 
conformation that is not fully inactive, but rather partially active (Dror et al., 2009). 
Despite the fact that a crystal structure might not be resolved without incorporation of 
recombinant receptor modifications, these modifications may introduce structural bias or 
artefacts that compromise the reliability of these structures (Deupi, 2014; Dror et al., 2009). It 
has been suggested that since the rhodopsin crystal structures do not contain artefacts from 
engineered stabilizing mutations they may be more reliable as models for comparison of 
inactive, partially active and active GPCRs (Deupi, 2014). 
The early rhodopsin-like receptor crystals included GPCR proteins co-crystalized with 
inverse agonists, which stabilize the inactive receptor state. These structures included the β1 
and β2-adrenergic receptors, A2A-adenosine, histamine H1 and dopamine D3 receptors (Warne 
et al., 2008; Doré et al., 2011; Shimamura et al., 2011; Chien et al., 2011). This was followed 
by crystal structures of receptors that bind larger peptide ligands including the opioid 
receptors and the CCR5 and CXCR4 chemokine receptors (Huang et al., 2015; Tan et al., 
2013; Wu et al., 2010). 
1.11.1. Overall fold  
The inactive rhodopsin-like GPCR crystal structures showed a similar structural fold 
to the inactive rhodopsin crystal. The fold is supported by conserved interactions of the highly 
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conserved amino acids and many interactions believed to be important in maintaining the 
inactive conformation of rhodopsin were confirmed in the rhodopsin-like receptor crystals 
(Chien et al., 2011; Doré et al., 2011; Shimamura et al., 2011; Wu et al., 2010; Dror et al., 
2009; Wu et al., 2012).  
1.11.2. Ionic-lock 
The ionic-lock was present in some of the inactive rhodopsin-like receptor crystals, 
including the D3 dopamine receptor and the A2A adenosine receptor, confirming that these 
receptors were in the inactive state (Chien et al., 2011; Doré et al., 2011; Huang et al., 2015). 
Several other rhodopsin-like receptor crystals, including the M2 muscarinic receptor, 
histamine H1 receptor and the β2-adrenergic receptor, did not display an ionic-lock (Dror et 
al., 2009; Huang et al., 2015; Shimamura et al., 2011; Haga et al., 2012). It has been 
suggested that the broken ionic-lock may be explained by stabilization of a conformation that 
is not fully inactive, by ligands that may be partial inverse agonists. For example, it has been 
suggested that the β2-adrenergic receptor in complex with dissociable ligands was not a fully 
inactive receptor crystal, but rather a crystal of an intermediate conformation, which does not 
contain an ionic-lock (Dror et al., 2009). Alternatively, the broken ionic-lock of inactive 
crystal structures incorporating the T4 lysozyme protein may result from presence and 
location of the T4 lysozyme in ICL3, which may hinder interactions of Arg
3.50 
with the Glu
6.30 
at the ICL3 end of TM6 (Dror et al., 2009). The inactive CCR5 chemokine receptor crystal 
displayed a modified ionic-lock due to the introduction of the thermostabilizing mutation, 
Ala
6.33(233)
Asp. The charged Asp forms a salt-bridge with Arg
3.50
, which
 
stabilizes the receptor 
in an inactive state (Tan et al., 2013). Like 80% of rhodopsin-like GPCRs (Mirzadegan et al., 
2003),  the µ-opioid receptor lacks an acidic Glu amino acid at position 6.30 of TM6 that can 
form a salt-bridge with the conserved Arg
3.50(163) 
of TM3. However, Arg
3.50(163) 
forms a 
hydrogen bond with a nearby Thr
6.34(279) 
instead (Huang et al., 2015). The GnRHR has an Arg
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in position 6.30 but, there is a Thr residue at position 6.33. Therefore, Thr
6.33(278)
 could mimic 
the role of Thr
6.34(279) 
of the µ-opioid receptor and form a similar alternative ionic-lock 
interaction in the GnRHR. 
1.11.3. Ligand binding pocket 
Binding pockets of GPCRs with small ligands, like the rhodopsin binding pocket, are 
largely within the TM domain. This allows for direct interactions with the highly conserved 
residues (Deupi et al., 2012). Comparisons of the ligand binding pockets across the different 
inactive GPCR crystals has highlighted a group of amino acid loci, which, regardless of the 
amino acid at the locus, contribute to a conserved ligand binding cradle. This ligand binding 
cradle includes the highly conserved Trp
6.48 
 sidechain (Venkatakrishnan et al., 2013). For 
example, inverse agonists complexed with the inactive CCR5 chemokine receptor, A2A 
adenosine receptor and histamine H1 receptors make direct contacts with the highly 
conserved Trp
6.48 
residue of the CWxPY motif to stabilize the inactive conformation
 
(Shimamura et al., 2011; Tan et al., 2013). However, Trp
6.48
 does not make direct contact 
with inverse agonists of the β2-adrenergic receptor (Deupi & Standfuss, 2011). It has been 
proposed that the inverse agonists that interact with Trp
6.48
 inhibit movement or rotation of 
TM6 (Foucaud et al., 2008; Trzaskowski et al., 2012). The binding pockets of rhodopsin-like 
GPCRs that bind large peptide-ligands are more extracellularly located when compared to 
rhodopsin or small ligands that bind at the same GPCR. For example, the peptide antagonist, 
CVX15, binds more to the extracellular domain of the CXCR4 chemokine receptor and makes 
fewer direct interactions with the highly conserved residues in the TM bundle (Trzaskowski et 
al., 2012; Wu et al., 2010). 
1.11.4. Water-mediated hydrogen bond networks  
Like rhodopsin, the rhodopsin-like GPCR crystal structures show cavities or channels 
within the TM core, which are thought to be supported by water molecules that stabilize 
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receptor folding (Hulme, 2013). The highly conserved residues of rhodopsin and rhodopsin-
like GPCRs hydrogen bond to water molecules forming a hydrogen bond network that is 
conserved among class A GPCRs. The conservation suggests that the network is important for 
GPCR structure (Huang et al., 2015; Pardo et al., 2007; Blankenship et al., 2015). In addition 
to the water molecules, high resolution crystal structures of the inactive β1-adrenergic, δ-
opioid, A2A adenosine and PAR1 protease-activated receptors show a sodium ion that co-
ordinates with the highly conserved, acidic, Asp
2.50
 side-chain via a salt bridge and with a 
number of water molecules, which interact with other highly conserved amino acid residues 
(Katritch et al., 2014; Liu et al., 2012). The sodium ion with its coordinated water molecules 
creates a link between the conserved Asp
2.50 
in TM2 and the conserved Trp
6.48
 and Asn
7.49 
residues in TMs 6 and 7 (Fenalti et al., 2014; Katritch et al., 2014; Nygaard et al., 2010; Liu 
et al., 2012). Since the sodium ion is known to be an allosteric inhibitor of GPCR signalling 
and is present only in the inactive structures, it is likely that the sodium ion stabilizes the 
hydrogen bonding network that maintains the inactive receptor state (Katritch et al., 2014; 
Nygaard et al., 2010). This stabilization may not be necessary for rhodopsin, which does not 
have the sodium ion, because it has a covalently bound inverse agonist ligand. Binding of 
agonist is proposed to displace the sodium ion towards the cytoplasm (Liu et al. 2012). 
Mutagenesis studies support a role for Asp
2.50
 in GPCR activation (Katritch et al., 2014). 
Sodium ions inhibit binding of GnRH agonists to the GnRHR at physiological 
concentrations (10mM), but have less effect on GnRH antagonist binding (Wormald et al., 
1985; Marian & Conn, 1980; Hazum, 1987; Hazum, 1981; Heitman et al., 2008), suggesting 
that sodium ions also allosterically inhibit the GnRHR. The GnRHR has Asn
2.50(87)
 instead of 
an Asp at position 2.50, but has an Asp
7.49(319)
 
 
instead of Asn at position 7.49. Mutagenesis 
studies suggest that the function of Asp
2.50 
of other GPCRs 
 
may be transferred to Asp
7.49(319) 
in the GnRHR. The Asn
2.50(87) 
is needed for GnRHR expression, but Asp
7.49(319) 
is required for 
25 
 
 
activation of G protein-dependent signalling (Flanagan et al., 1999). It is possible that the Asp 
at position 7.49 is part of the sodium ion/water network of the GnRHR. In summary, 
compared with rhodopsin, rhodopsin-like GPCRs have sodium ions and a larger cytoplasmic 
water-mediated polar network, which act together to stabilize the inactive receptor 
conformation in the absence of a covalently bound inverse agonist (Huang et al., 2015; 
Standfuss et al., 2011).  
1.12. Crystal structures of active rhodopsin 
When photons of light interact with the retinal that is covalently bound to rhodopsin in 
photoreceptor cells, retinal isomerizes, changing from “bent” 11-cis-retinal to “straight” all-
trans-retinal (Shichida & Morizumi, 2007). The longer “straight” all-trans-retinal cannot be 
accommodated within the binding pocket defined by the inactive rhodopsin structure. The 
opsin apoprotein undergoes conformational transitions through several intermediate states, 
each corresponding to a specific spectroscopic absorption profile. These include 
photorhodopsin, bathorhodopsin, lumirhodopsin, and metarhodopsin I before the active 
metarhodopsin II conformation is formed (Zhou et al., 2012). Metarhodopsin II is unstable 
with all-trans-retinal bound and consequently splits into active opsin apoprotein and free all-
trans-retinal. The active opsin binds and activates the G protein, transducin, which then 
activates downstream signalling pathways (Zhou et al., 2012).  
As was the case for the inactive receptor structures, rhodopsin was also the first GPCR 
to be crystalized in the active state. Rhodopsin was initially crystalized in spectroscopically-
defined, partially active states, including metarhodopsin I, which provided insight into the 
process of activation, but did not define the fully active conformation (Ruprecht et al., 2004; 
Deupi et al., 2012; Deupi, 2014). A fully active, ligand-free rhodopsin structure was then 
crystallized in complex with a synthetic peptide derived from the carboxy terminus of the α 
subunit of transducin (GαCT) to stabilize the active conformation (Scheerer et al., 2008). A 
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limitation of the ligand-free opsin structure is that it does not reveal how agonist binding 
initiates the transition of the receptor from inactive to active conformation. Therefore, two 
constitutively active rhodopsin mutants were co-crystallized with all-trans-retinal and a GαCT 
peptide to give insight into the ligand binding pocket of active rhodopsin (Deupi et al., 2012; 
Standfuss et al., 2011). These crystals are examples of two types of constitutively active 
mutant rhodopsin crystal structures. The first type contains a mutation (Glu
3.28(113)
Gln) of the 
binding pocket, that has unchanged amino acid sequence around the G protein binding site, 
allowing investigation of G protein binding (Standfuss et al., 2011). The second constitutively 
active rhodopsin had a mutation, Met
6.40(257)
Tyr, near the G protein binding site, but an un-
mutated retinal binding pocket that was compared with other rhodopsin structures to identify 
the ligand-interacting residues of the active receptor conformation (Deupi et al., 2012). The 
constitutively active mutants were confirmed as being fully active Metarhodopsin II-like 
structures by spectroscopic characterization (Deupi et al., 2012; Standfuss et al., 2011). 
1.12.1. Ligand binding pocket 
When compared with inactive rhodopsin, active rhodopsin crystals show a larger 
binding pocket, which accommodates the longer “straight” all-trans-retinal configuration 
(Deupi & Standfuss, 2011). The larger binding pocket results from outward movement of the 
extracellular end of TM6, together with repositioning of bulky side-chains during receptor 
activation (Deupi et al., 2012). During retinal isomerization, the β-ionone ring of all-trans-
retinal moves 4.3Å into a space between TMs 5 and 6 forcing the outward rotation of TM6. 
The Trp
6.48(265) 
side-chain, which interacts with the methyl group on C18 of the β-ionone ring 
in the inactive rhodopsin crystal, shows a co-ordinated movement of 3.6Å that maintains its 
interaction with the retinal during transition to the active conformation (Standfuss et al., 
2011).  
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Metarhodopsin II crystals were also prepared by incubating the wild type apoprotein 
with all-trans-retinal, which became covalently bound. One of these active crystals included a 
GαCT peptide, whereas the other was prepared without the G protein mimetic. The ligand 
binding pockets of these structures were similar to those of the constitutively active mutant 
rhodopsins, except for the presence of a hydrophobic interaction of C15 of all-trans-retinal 
with Met
2.53(86)
 (Choe et al., 2011). Compared with inactive rhodopsin, active rhodopsin 
showed a structural rearrangement of the back-bone of TM2 around a Gly
2.56(89)
-Gly
2.57(90) 
motif that causes movement of the side-chain of Met
2.53(86)
. The movement of the Met
2.53(86) 
and Trp
6.48(265) 
side-chains away from their central location within the TM core of rhodopsin, 
is reported to allow water molecules to penetrate further into the central core of the TM 
bundle of the active receptor (Deupi et al., 2012; Choe et al., 2011). 
1.12.2. Unchanged Pro6.50 kink and rotation via Trp6.48 
Specific residues within the conserved GPCR motifs, such as Trp
6.48
, are believed to 
have a conserved role in GPCR activation (van Rhee et al., 2011; Mayevu et al. 2015; Wu et 
al., 2012; Kobilka, 2007; Hulme 2013). Biophysical studies showed an outward motion of the 
cytosolic end of TM6 during rhodopsin activation, which was associated with the conserved 
Pro
6.50 
of the CWxPY motif (Hubbell et al. 2003). The Pro
6.50 
was predicted to serve as a 
hinge that moved TM6 by changing the angle of the bend in the helix (Trzaskowski et al., 
2012; Tehan et al., 2014; Altenbach et al., 2008). However, the crystal structures of activated 
rhodopsin show that TM6 undergoes a whole body movement that is rotational, rather than 
hinged, and has an unchanged bend angle at the proline-kink in the CWxPY motif. This 
rotational outward movement of the cytosolic end of TM6 is associated with movement of 
Trp
6.48 
of the CWxPY motif, which changes its position in response
 
to retinal isomerization 
and movement of the β-ionone ring (Standfuss et al., 2011; Mayevu et al., 2015). The 
constitutively active Glu
3.28(113)
Gln rhodopsin mutant structure showed that the movement of 
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the cytosolic end of TM6 is amplified by the presence of the exaggerated bend angle of 
Pro
6.50(267) 
(Standfuss et al., 2011). The crystal structures of constitutively active rhodopsin 
mutants were similar at the cytoplasmic side, showing that the agonist ligand is enough to 
stabilize a fully active conformation of rhodopsin in the absence of a G protein peptide (Choe 
et al., 2011). 
1.12.3. Open ionic-lock  
Another difference observed in the active˗ compared with the inactive˗ rhodopsin 
crystal structures was the open ionic-lock between residues in TMs 3 and 6, which results 
from the outward rotation of the cytosolic end of TM6 in response to retinal isomerization 
(Standfuss et al., 2011). The opsin apoprotein crystals show that the side-chain of Arg
3.50(135)
, 
(which is freed when the ionic lock connecting it to Glu
3.49(134)
 and Glu
6.30(247) 
is broken by 
movement of TM6,) 
 
is positioned near the side-chains of the conserved residues Tyr
5.58(223)
 of 
TM5 and Tyr
7.53(306)
 (of the NPxxY
7.53
 motif in TM7). Compared with inactive rhodopsin, the 
Tyr
5.58(223)
 and Tyr
7.53(306) 
side-chains are rotated inward towards Arg
3.50(135)
 (Goncalves et al., 
2010; Hoffmann et al., 2000). More recently, a high resolution structure of activated opsin, 
which shows a more complete water network, revealed direct interaction of Arg
3.50(135) 
with 
Tyr
5.58(223)
, which then makes a water-mediated hydrogen bond with Tyr
7.53(306) 
(Blankenship 
et al., 2015).
 
The close proximity of Tyr
5.58(223)
, Tyr
7.53(306) 
and Arg
3.50(135)
 in the active 
structure suggests that these interactions may contribute to stabilizing the active state of 
rhodopsin (Goncalves et al., 2010). The functional importance was supported by the 
constitutively active Met
6.40(257)
Tyr
 
rhodopsin
 
structure in which the hydroxyl group of the 
mutant Tyr
6.40(257)
 side-chain mimics the hydroxyl of a water molecule that is part of this 
interaction (Blankenship et al., 2015). The mutant Tyr
6.40(257)
 residue also destabilizes the 
inactive receptor state by disrupting the hydrophobic barrier that is present in the inactive 
receptor and absent from the active receptor structure (Deupi et al., 2012). The absence of the 
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hydrophobic barrier allows formation of a continuous hydrophilic channel that extends from 
the ligand binding pocket to the G protein binding site in the active rhodopsin structure 
(Tehan et al., 2014; Deupi 2014). 
1.12.4. Water-mediated hydrogen bond network  
Like the inactive structures, active rhodopsin structures showed water molecules that 
form hydrogen bonding networks. Molecular modelling that involved omission of structural 
water molecules from active rhodopsin showed a disordered structure, whereas the structure 
with the waters present was more energetically favourable and stable, supporting structural 
importance of the water (Standfuss et al., 2011). Two active rhodopsin crystal structures with 
enlarged retinal binding pockets showed water-mediated hydrogen bond interactions that 
differ from the network in the inactive rhodopsin crystals. This suggests that each set of 
hydrogen bond networks specifically stabilizes either the active or the inactive receptor 
conformation (Choe et al., 2011). This observation in rhodopsin led to a proposal that the 
water molecules may be conserved structural elements of GPCRs that participate in the 
activation process and facilitate coupling to G proteins (Standfuss et al., 2011; Pardo et al., 
2007).  
A high resolution structure of activated opsin revealed that water molecules can be 
divided into three categories, based on their apparent roles (Blankenship et al., 2015). One set 
of water molecules occupied similar positions in both the inactive and the active 
conformations, suggesting that they have a structural, rather than a signalling, role. A second 
set of water molecules was present in both the active and inactive rhodopsin structures and 
maintained hydrogen bonding with the same residue in both conformations, although the 
amino acid side-chains moved. It is likely that these water molecules facilitate movement and 
repositioning of the interacting residues. The final set of water molecules were observed to be 
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in different positions in the inactive and active rhodopsin structures, suggesting a role in 
stabilizing a single receptor conformation (Blankenship et al. 2015).  
The water network of the active rhodopsin structure creates a continuous hydrophilic 
channel from retinal in the binding pocket to the G protein-binding site when the hydrophobic 
barrier of the inactive receptor conformation is broken (Standfuss et al., 2011; Blankenship et 
al., 2015) and the Met
2.53(86) 
and Trp
6.48(265) 
side-chains move away from the centre of the TM 
bundle (Choe et al., 2011; Deupi et al., 2012). The altered arrangement of the water network 
of the active rhodopsin crystals arises from a rearrangement of water-mediated hydrogen 
bonds between highly conserved residues, including Trp
6.48(265) 
of TM6. A subsequent review 
of the rhodopsin structures proposed a conserved water-mediated interaction of the less 
obviously conserved residue in position 2.53 with the conserved Trp
6.48(265) 
 in class A GPCRs
 
(Deupi, 2014). This suggested to us that the side-chain of the Glu
(2.53)90 
residue of the GnRHR 
may interact with Trp
(6.48)280
. Thus, the HH-associated Glu
(2.53)90
Lys mutation may disrupt 
GnRHR expression by disrupting this interaction.  
1.13.  Active rhodopsin-like GPCR crystal structures  
Based on theoretical models of GPCR activation, it is expected that GPCRs must be 
co-crystalized with agonist ligands to obtain structures of active GPCR conformations. Unlike 
the case for rhodopsin, it was found that simple agonist binding was not sufficient to obtain 
fully active structures. Rather, agonist-bound GPCRs had to be co-crystalized with a G 
protein or G protein mimetic to stabilize the high agonist affinity GPCR conformation that 
defines the fully active receptor state (Dror et al., 2012; Nygaard et al., 2013; Sounier et al., 
2015). Therefore, several agonist-bound GPCR crystals, such as the agonist-bound A2A 
adenosine and rat neurotensin (NTSR1) receptors, which did not include G protein mimetics, 
were only partially active structures (Lebon et al., 2011; Xu et al., 2011; White et al., 2012). 
Based on comparisons with partially and fully active rhodopsin crystals (see section 1.12), 
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these structures did not exhibit the full extent of movement of TMs 6 and 7 (Xu et al., 2011). 
An exception is the highly constitutively active viral GPCR, US28, in complex with the 
CX3CL1 chemokine ligand, which showed very similar structures when crystallized with- or 
without- the G protein mimetic, Nb7 (Burg et al., 2015). 
Since co-crystallization of G proteins is difficult to achieve, G protein mimetics have 
been incorporated into GPCR crystallography. Commonly used G protein mimetics include 
antibody Fab fragments (Steyaert & Kobilka, 2011) or nanobodies (very small antibodies 
produced by llamas), which were selected for their ability to stabilize the high agonist binding 
affinity GPCR conformation (Rasmussen et al., 2011a). Whereas these antibodies may mimic 
the effect of the G protein on receptor conformation, they are likely to make slightly different 
binding contacts with receptors (Rasmussen et al., 2011a). This review will focus primarily 
on the fully active rhodopsin-like GPCR structures.  
1.13.1. Ligand binding pocket 
Although ligand binding pockets of active GPCR crystals must differ to accommodate 
the binding of their different ligands, it has been observed that many ligands contact the 
highly conserved residues, including Trp
6.48
.
 
This suggests a globally conserved role for such 
residues in the activation of class A GPCRs and Trp
6.48 
has even been proposed to be part of a 
conserved binding pocket (Venkatakrishnan et al., 2013). Not all agonist ligands make direct 
contact with Trp
6.48. The crystal structures of the active β2-adrenergic receptor showed no 
direct contact of agonist with Trp
6.48(286)
, although it forms part of the ligand binding pocket 
(Rasmussen et al., 2011). Similarly, the recent description of chemokine GPCR crystal 
structures make no mention of agonist interaction with the Trp
6.48 
residue (Burg et al., 2015; 
Qin et al., 2015). In contrast, Trp
6.48(264) 
was shown to contact the agonist ligand in the human 
A2A adenosine crystal (Xu et al., 2011). 
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Although some peptide ligands partially enter the TM core of receptors (Wu et al., 
2010; Standfuss, 2015), because of their larger size, it has long been expected that peptides 
would bind more extracellularly making contact with the extracellular loops and the upper 
part of the TM bundle (Shonberg et al., 2014). It has also been predicted
 
that some peptide 
and protein ligands bind exclusively to the extracellular domains of GPCRs (Krumm & 
Grisshammer, 2015). This mode of binding would limit the contact of such ligands with 
conserved residues that are located within the TM bundle (Berthold & Bartfai, 1997; 
Shonberg et al., 2014). Supporting this, crystal structures of the peptide agonist-bound 
NTSR1 neurotensin receptor, showed an open ligand binding pocket exclusively on the 
extracellular surface of the receptor (White et al., 2012; Egloff et al., 2014; Krumm et al., 
2015). The carboxy terminus of the peptide ligand interacts with two Arg residues near the 
extracellular surface. The Arg side-chains make hydrogen bonds with Tyr
6.51 
of the CWxPY 
motif. The Tyr
6.51 
forms hydrophobic stacking interactions with Phe
7.42
, which mediates 
planar interactions with Trp
6.48
. The Trp
6.48
 then makes hydrophobic stacking interactions 
with the conserved Phe
6.44
,
 
which is part of the hydrophobic core activation switch (Krumm et 
al., 2015; Tehan et al., 2014). This suggests a role for
 
Trp
6.48 
in coupling extracellular agonist 
binding to the conserved activation switches of the NTSR1 receptor.  
We propose that, like neurotensin, GnRH interacts largely with the extracellular 
domain of the GnRHR. This is supported by site-directed mutagenesis studies that have 
identified only residues that are extracellular to the conserved network as ligand contacts 
(Millar et al., 2004; Mayevu et al., 2015). Earlier reports proposed an interaction of Trp
6.48
of 
the GnRHR with Trp
3 
of the GnRH ligand (Chauvin et al., 2000; Davidson et al. 1994; 
Karges et al., 2003). However, systematic mutagenesis of Trp
6.48(280) 
to Ala, His, Ser, Gln and 
Met affected only expression of mutant GnRHR proteins and had no effect on GnRH binding 
affinity or GnRH signalling (Coetsee et al., 2006). A separate study showed that mutation of 
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Trp
6.48(280) 
to Phe had small effects on GnRH binding affinity, but had a larger effect on 
affinity of a small molecule antagonist that was predicted to bind more deeply within the TM 
bundle (Betz et al., 2006). This supports the idea that ligands that bind more deeply within the 
TM bundle may contact the Trp
6.48
, whereas the GnRH peptide probably does not (Betz et al., 
2006).  
The residue at position 2.53 has not generally been considered to be a ligand 
contacting residue (Madabushi et al., 2004; Rodriguez et al., 2010). Of all the GPCRs 
crystallized up to 2013, only the human κ-opioid receptor showed direct contact of its ligand, 
an antagonist, with the residue in position 2.53 (Venkatakrishnan et al., 2013; Wu et al., 
2012), which is also supported by site-directed mutagenesis studies (Vortherms et al., 2007).  
Mutagenesis studies suggest no direct contact of Glu
2.53(90) 
of the GnRHR with the 
GnRH peptide. Although, mutation of Glu
2.53(90) 
to Lys abolishes GnRHR function, when 
expression of the mutant receptor is rescued, its GnRH binding affinity is the same as in the 
wild type GnRHR (Tello et al., 2012; Conn & Janovick, 2009; Chevrier et al., 2011), as was 
the case for mutations of Trp
6.48(280)
 (Coetsee et al., 2006). The unchanged GnRH binding 
affinities of GnRHRs with mutations of Glu
2.53(90) 
and Trp
6.48(280) 
suggest that neither of these 
residues directly contacts the ligand. Therefore it is likely that Glu
2.53(90) 
and Trp
6.48(280) 
 have 
structural roles in the GnRHR that contribute to receptor expression, but they do not contact 
peptide ligands.  
1.13.2. Overall fold and movement of TMs 
The overall fold of a nanobody-stabilized β2-adrenergic receptor structure was nearly 
identical to the β2-adrenergic receptor in complex with the Gs protein, especially around the 
most highly conserved residues. This confirmed that the nanobody, Nb80, stabilized a fully 
active conformation of the β2-adrenergic receptor by effectively mimicking the structural 
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effects of G protein binding (Rasmussen et al., 2011a; Rasmussen et al., 2011b; Huang et al., 
2015).  
Both the Gs-coupled and nanobody-stabilized active structures of the β2-adrenergic 
receptor showed outward movement of the cytosolic end of TM6 and repositioning of 
Tyr
7.53(326) 
of the NPxxY motif near Arg
3.50(131)
, as was seen for rhodopsin (Rasmussen et al., 
2011a; Rasmussen et al., 2011b; Ring et al., 2013). The β2-adrenergic receptor was 
subsequently crystallized in complex with a different nanobody, Nb6B9, and three different 
agonists including the natural ligand, adrenaline (Ring et al., 2013). Although the agonists in 
the Nb6B9-stabilized β2-adrenergic receptor structures were chemically diverse, the receptor 
structures showed similar overall folds. A notable similarity between the Gs- and nanobody-
stabilized active β2-adrenergic receptor structures is that, as was the case for  rhodopsin, there 
is no switch of the Trp
6.48
 side-chain rotamer (Shonberg et al., 2014). In rhodopsin, the Trp
6.48 
shifts position because retinal pushes it aside during isomerization, whereas in the active β2-
adrenergic receptor structures, Trp
6.48 
is
 
shifted because the surrounding TMs “push” TM6 
(Rasmussen et al., 2011a; Rasmussen et al., 2011b; Ring et al., 2013). Although the Gs- and 
nanobody-stabilized β2-adrenergic receptor structures differ very slightly overall, the 
discrepancies noted are mostly at the cytosolic ends of TMs 5 and 6, because the receptors 
interact with different proteins, namely the G protein or the nanobody. Nevertheless, the 
structures are nearly identical around the highly conserved motifs, such as DRY and NPxxY 
at the cytosolic ends of TMs 3 and 7 respectively (Rasmussen et al., 2011b).  
Comparison of the inactive and active structures of the M2 muscarinic receptor 
supports outward movement of TM6 and inward movement of TM7 that is similar to 
structures of rhodopsin and the β2-adrenergic receptor (Shonberg et al., 2014). The high-
resolution active µ-opioid receptor structure showed a similar outward movement of TM6 that 
was stabilized by a clearly defined water-mediated hydrogen bonding network (Huang et al., 
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2015). Combined with NMR spectral studies, the increasing number of crystal structures 
suggests that the movements of TMs 5, 6 and 7 are conserved features of the activation 
process of rhodopsin-like GPCRs (Nygaard et al., 2013; Shonberg et al., 2014). Thus, 
although the agonist ligand binding pockets differ among class A GPCRs, the structures at the 
intracellular side of the receptors, which interact with the G proteins, are largely similar 
(Huang et al., 2015; Sounier et al., 2015).  
1.13.3. Open ionic-lock 
The active rhodopsin-like GPCRs typically display an open ionic-lock, as movement 
of TMs 3 and 6 away from each other breaks the salt-bridge between Arg
3.50 
and Glu
6.30 
that 
restrains the receptor in the inactive state (Rasmussen et al., 2011a). It has been proposed that 
in addition to the ionic lock, a water-mediated hydrogen bonding network at the intracellular 
side of GPCRs stabilizes an inactive conformation and that binding of the G protein 
destabilizes this network to allow receptor activation (Huang et al., 2015).  
Like the active rhodopsin structures (Blankenship et al., 2015), the high-resolution µ-
opioid receptor structure shows that Arg
3.50 
interacts with Tyr
5.58
, which hydrogen bonds via 
water to Tyr
7.53
 (Huang et al., 2015). However, in the Nb80-stabilized β2-adrenergic receptor 
structure, this interaction is prevented by interaction of Arg
3.50(131) 
with the nanobody 
(Rasmussen et al., 2011a). Subsequent nanobody-stabilized high resolution structures of the 
β2-adrenergic receptor, allowed clear mapping of many water molecules (Ring et al., 2013). 
These active structures showed a water-mediated hydrogen bond between Tyr
5.58(219) 
and 
Tyr
7.53(326)
 as was seen in active rhodopsin (Shonberg et al., 2014; Blankenship et al., 2015). 
The Gs-stabilized β2-adrenergic receptor showed that Arg
3.50(131) 
forms parts of the open ionic-
lock and also interacts with Gs (Rasmussen et al., 2011b). However, the lower resolution of 
this structure did not allow mapping of many water molecules and the water-mediated 
hydrogen bond between Tyr
5.58(219) 
and Tyr
7.53(326) 
was not noted (Rasmussen et al., 2011b). 
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Despite some variations, the active structures of rhodopsin-like GPCRs show interactions 
between highly conserved residues that are repositioned close enough to interact directly, or 
indirectly via water, because of the opening of the ionic lock (Blankenship et al., 2015; Huang 
et al., 2015; Romo et al., 2010). 
1.13.4. Water-mediated hydrogen bonding networks  
As with rhodopsin, rhodopsin-like GPCRs have a network of polar interactions 
extending from the ligand binding pocket to the G protein-binding surface (Huang et al., 
2015). In contrast to the inactive structures, the active structures do not contain sodium ions. 
The movement of TMs 6 and 7 during activation changes the size of the sodium binding 
pocket such that the sodium ion is unable to bind within the confined space. The TM 
movement is thought to expel the sodium ion to the cytoplasmic side (Liu et al., 2012; 
Katritch et al., 2014). The agonist-bound NTSR1 neurotensin receptor structures show that 
Trp
6.48(321) 
forms water-mediated hydrogen bonds with other residues of the sodium ion 
binding pocket that occlude access of the sodium ion (Krumm et al., 2015). 
Like rhodopsin, the nanobody-stabilized active β2-adrenergic receptor showed a 
continuous water channel. It was proposed that the structural rearrangements of TMs during 
receptor activation are associated with changes in this water network that stabilize inactive 
and active states (Rasmussen et al., 2011a). A detailed analysis of the water molecules in the 
high resolution structure of the active µ-opioid receptor showed that the water molecules 
interact predominantly with the highly conserved residues in rhodopsin-like GPCRs, 
connecting them via a hydrogen-bonding network. Low resolution structures of active 
GPCRs, in which water molecules could not be resolved, showed highly conserved residues 
in the same positions as they are in the high resolution active µ opioid receptor structure. 
Therefore, it is suggested that water molecules may be present and form a similar hydrogen-
bonding network in all active GPCRs (Huang et al., 2015). Notably, as in rhodopsin, the 
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highly conserved Trp
6.48(293) 
makes water-mediated contacts with other structurally important 
residues (Asp
2.50(114)
, Asn
3.35(150)
, Ser
3.39(154)
) that contribute to activation of the µ-opioid 
receptor (Huang et al., 2015). Based on this, the Trp
6.48(280) 
residue of the GnRHR may make 
water-mediated interactions with the equivalent residues Asn
2.50(87)
, Ser
3.35(124) 
and Tyr
3.39(126)
. 
 
1.14. The relationship between the residue at the 2.53 locus and the conserved Trp6.48  
1.14.1. Class A GPCRs 
90% of Class A GPCRs have an aromatic amino acid at position 6.48 and of these, 
90% are Trp (Mirzadegan et al., 2003). It is well established that the highly conserved Trp
6.48 
residue
 
is important for GPCR function (Ahuja & Smith, 2009; Malherbe et al., 2014; 
Trzaskowski et al., 2012; Yuan et al., 2014). Although, the amino acid at position 2.53 has 
not usually been considered a conserved residue, a high proportion of rhodopsin-like GPCRs 
(69%) have large and hydrophobic residues (Ile, Met and Val) at position 2.53, whereas acidic 
residues are rare (2%) (Mirzadegan et al., 2003). Because the side-chain of the residue at 
position 2.53 is usually hydrophobic, it was not considered in analyses of conserved 
hydrophilic interactions (Venkatakrishnan et al., 2013) or the conserved water-mediated 
hydrogen bond network (Huang et al., 2015). However, evolutionary trace analysis identified 
Met
2.53(86) 
of rhodopsin among the top 20% of conserved residues in class A GPCRs. The 
analysis showed that Met
2.53(86) 
is not involved in any retinal-specific functions of rhodopsin, 
but it is likely to be important in all class A GPCRs (Madabushi et al., 2004). Substituted 
cysteine accessibility method (SCAM) analysis of the D2 dopamine receptor showed that the 
Val
2.53(83) 
side-chain is oriented towards the water-accessible core of the TM bundle (Javitch 
et al., 1999), where it may form intra-molecular interactions. Nuclear magnetic resonance 
(NMR) analysis of the β2-adrenergic receptor showed that the environment of the Met2.53(86)  
side-chain was different between active and inactive receptor conformations. It was suggested 
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that change in the environment of the Met
2.53(86) 
resulted from a change in its distance from 
Trp
6.48(286)
 (Kofuku et al., 2012; Nygaard et al., 2013). It is possible that an interaction 
between these residues that is present in the inactive, but absent from the active conformation 
of the β2-adrenergic receptor causes repositioning of the side-chains. The changed 
environment may also reflect protonation of the nearby Asp
2.50
, which is the counter ion of the 
sodium ion that stabilizes the inactive structure (Dror et al., 2009; Ranganathan et al., 2014; 
Liu et al., 2012). It was proposed that Trp
6.48 
and Met
2.53 
are part of a conserved “ligand 
sensing” region of GPCRs where residues that are not part of the ligand binding pocket are 
allosterically coupled to ligand binding (Madabushi et al., 2004). The observation by Deupi et 
al that movement of Met
2.53(86) 
and Trp
6.48(293) 
in rhodopsin in response to retinal isomerization 
contributes to opening of the hydrophilic channel is consistent with this (Deupi et al., 2012; 
Deupi, 2014). A follow-up evolutionary trace study found that mutation of Val
2.53(83) 
of the D2 
dopamine receptor decreases dopamine binding affinity. It was concluded that Val
2.53(83)
 is 
“part of a set of less conserved residues outside of the ligand binding pocket that couple 
agonist binding to the highly conserved switch residues”. Specifically, Val2.53(83) was proposed 
to communicate with Trp
6.48 
and/or Tyr
6.51 
of the CWxPY motif, via intramolecular water 
molecules (Rodriguez et al., 2010). A recent analysis of conserved direct inter-helical 
interactions, including hydrophobic interactions in all GPCR crystals, showed that the residue 
at the 2.53 locus, regardless of the amino acid present, interacts directly with the residue at the 
3.35 locus in TM3. It was also found that Trp
6.48 
 makes conserved direct interactions with 
residues at the adjacent locus 3.36 and the 7.42 locus (Cvicek et al., 2016). The conserved 
interactions of the residues at 2.53 and 6.48 respectively, with the neighbouring loci, 3.35 and 
3.36, in TM3 of all GPCR crystals imply that the side-chains of the 2.53 and 6.48 residues 
must be positioned close to each other. The interactions with TM3 are present in both active 
and inactive structures, showing that changes in these interactions probably do not constitute 
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part of the conserved GPCR activation mechanism. However, these interactions are likely to 
have structural roles that affect receptor folding and the configuration of the ligand binding 
pocket (Cvicek et al. 2016; Madabushi et al. 2004). Thus, mutations of these residues may 
disrupt receptor expression, but may also distort the ligand binding surface, affecting affinity, 
or disrupt coupling to the conserved activation switches, affecting signalling. We reviewed 
the effects of mutagenesis of the residues in the 2.53 locus of class A GPCRs and the results 
are summarized in table 1.2. Mutagenesis of the locus 2.53 residue had varying effects in 
different receptors, including disrupting receptor expression, decreased agonist and/or 
antagonist binding affinity and constitutive activity in the case of the thyroid-stimulating 
hormone receptor. This indicates that the residue in the 2.53 locus of class A GPCRs has 
diverse roles in receptor folding and configuration of the ligand binding pocket, but is mostly 
not directly involved in ligand binding.  
1.14.2.  GnRHRs 
Trp
6.48 
is 100% conserved in GnRHRs (Millar et al., 2004) and was proposed to be a 
ligand-contacting residue that is directly involved in binding of peptide ligands (Söderhäll et 
al., 2005; Chauvin et al., 2001). However, systematic mutagenesis of the Trp
6.48(280) 
residue 
disrupted GnRHR expression, but had no effect on signalling or binding affinity (Betz et al. 
2006; Coetsee et al., 2006). This suggests that Trp
6.48(280) 
has a role in maintaining the 
structural stability of the GnRHR, but does not directly contact the ligand. 
The Glu side-chain is a carboxylic (COOH) acid, which can be either negatively 
charged (COO
-
) or uncharged (COOH), depending on the pH of its microenvironment within 
the protein (Betts & Russell, 2007). It has been proposed that the Glu
2.53(90)
 residue of the 
GnRHR forms an intramolecular salt-bridge with the basic side-chain of Lys
3.32(121)
 in TM3 
(Janovick et al., 2011; Janovick et al., 2009; Stewart et al., 2012; Hoffmann et al., 2000). It 
was suggested that the presence of the basic Lys side-chain in position 2.53(90) of the HH-
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associated Glu
2.53(90)
Lys GnRHR
 
mutant disrupts receptor folding by disrupting the proposed 
intramolecular salt-bridge (Janovick et al., 2011; Blomenröhr et al., 2001; Stewart et al., 
2012; Janovick et al., 2009; Tello et al., 2012).  
Although Glu
2.53(90) 
is conserved in mammalian type I GnRHRs, non-mammalian˗ and 
type II˗ GnRHRs have large hydrophobic residues (Val, Met or Leu) in position 2.53 (Millar 
et al., 2004). Combined with presence of hydrophobic residues at position 2.53 in other 
rhodopsin-like GPCRs, this suggests that the carboxyl group of Glu
2.53 
may not be important 
in the function of GnRHRs. This is supported by a mutation of the Glu
2.53(90) 
residue in the 
mouse GnRHR to uncharged, Gln, which resulted in a mutant receptor that was 
indistinguishable from the wild type GnRHR (Flanagan et al., 1994). Since the Glu
2.53(90)
Gln 
GnRHR raises questions about the proposed salt-bridge interaction of the Glu
2.53(90)
,
 
 it is 
unclear why the Glu
2.53(90)
Lys mutation disrupts GnRHR folding.  
This project has investigated the chemical properties of the Glu
2.53(90)
 side-chain that 
might explain the effects of the Glu
2.53(90)
Lys and Glu
2.53(90)
Gln mutations, using systematic 
site-directed mutagenesis of Glu
2.53(90)
. Since crystal structures of class A GPCRs show 
conserved orientation of the side-chains at position 2.53 toward the hydrophilic centre of the 
TM bundle (Deupi, 2014; Deupi & Standfuss, 2011; Cvicek et al., 2016), it is likely that the 
Glu
2.53(90) 
side-chain is oriented towards the core of the TM bundle of the inactive GnRHR. 
Proposals of a water-mediated interaction between the residue at the 2.53 locus
 
and the 
conserved Trp
6.48
 in class A GPCRs (Deupi, 2014; Deupi & Standfuss, 2011), suggest that the 
side-chains of these residues may be oriented toward each other within the TM bundle of the 
GnRHR. This suggests that mutating these residues may disrupt GnRHR expression by 
disrupting the conserved water network. To test for a possible interaction of Glu
2.53(90) 
with 
Trp
6.48(280)
, we also mutated the Trp
6.48(280) 
residue of the GnRHR. The more recent report that 
the residues at the 2.53 and 6.48 loci make conserved direct interactions (Cvicek et al., 2016) 
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suggests that Glu
2.53(90) 
and Trp
6.48(280) 
may interact respectively with the Ser
3.35(124) 
and 
Met
3.36(125) 
residues of the GnRHR. This would also support roles for Glu
2.53(90) 
and Trp
6.48(280) 
in GnRHR structure and function. Mutagenesis of Ser
3.35(124)
 to Ala preserved wild type 
GnRHR function, whereas, mutation to Asp abolished receptor function (Betz et al., 2006),
 
suggesting that introduction of Asp instead of Ala in close apposition to Glu
2.53(90) 
may disrupt 
GnRHR expression. This proposal also places the side-chains of Glu
2.53(90) 
and Trp
6.48(280) 
within a shared environment via interaction with adjacent residues in TM3 of the GnRHR. 
This study has used additional site-directed mutagenesis of Trp
6.48(280) 
to assess its role in 
configuration of the ligand binding pocket of the GnRHR in addition to its structural role. 
Thus, the aim of this study was to determine the role of the chemical properties of the 
Glu
2.53(90)
 side-chain in GnRHR structure and function, using systematic site-directed 
mutagenesis of Glu
2.53(90)
. Trp
6.48(280) 
was also mutated to investigate a possible relationship 
with Glu
2.53(90) 
in the GnRHR. Mutant and wild type GnRHR constructs were transiently 
transfected into COS7 cells. Mutant receptors were assessed for inositol phosphate signaling 
to test functional capacity and radioligand binding assays were performed as a means of 
testing for receptor expression relative to wild type GnRHRs. 
As summarized in table 3.1, we show that small amino acid substitutions for Glu
2.53(90) 
(Asn, Ser) abolish GnRH-stimulated IP production and ligand binding, suggesting disruption 
of GnRHR expression. Addition of a carboxy-terminal tail, which enhances Glu
2.53(90)
Lys 
receptor expression, did not yield measurable IP production or ligand binding in these mutant 
GnRHRs. The Glu
2.53(90)
Ala mutation, which removes the carboxyl side-chain of Glu
2.53(90) 
and introduces only a methyl group, abolished GnRHR function, which was only partially 
recovered by addition of the carboxy-terminal. A conservative substitution with Asp, which, 
like Glu, has a COOH side-chain, also completely abolished IP production and ligand 
binding, both in the absence and presence of a carboxy-terminal tail. This indicates that 
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presence of a COOH group does not stabilize GnRHR expression, showing that the 
conservative acidic Asp is less well tolerated than the basic Lys side-chain. In contrast, 
substitution of Glu
2.53(90) 
with large, uncharged (Phe, Leu, Gln) amino acids results in robust 
IP production and ligand binding with wild type-like GnRH affinity. The unchanged affinities 
show that Glu
2.53(90) 
is not part of the GnRHR ligand binding pocket. To confirm that 
Glu
2.53(90) 
does not form a salt-bridge with a positively-charged residue, we substituted 
Glu
2.53(90) 
with Arg. Surprisingly, the Arg substitution preserves GnRH-stimulated IP 
production, even without a carboxy-terminal tail. This shows that the GnRHR is well-
expressed with a basic residue at the 2.53 locus. However, GnRH had lower potency and 
affinity suggesting that the Arg mutation distorts the ligand binding pocket. Based on 
proposals that the residue at the 2.53 locus of other GPCRs may interact with the conserved 
Trp
6.48 
via the water-mediated hydrogen bond network (Deupi, 2014), we mutated Trp
6.48(280) 
of the GnRHR. Substitution of Trp
6.48(280)
 with Arg also decreased GnRH potency and binding 
affinity, suggesting that this Arg side-chain also distorts the ligand binding pocket. Our results 
suggest that Glu
2.53(90) 
might not directly interact with Trp
6.48(280)
,
 
but that these two residues 
have a similar role in maintaining the overall GnRHR fold that contributes to stable cell 
surface expression of the receptor. 
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GPCR Residue  Reference 
β2-adrenergic  Met(82) Not directly involved in ligand binding, NMR spectroscopy shows environment of 2.53 side-chain 
changes upon receptor activation 
(Kofuku et al., 2012) (Nygaard 
et al., 2013) 
Serotonin  
(5-hydroxytryptamine) 
5HT2B   
Val(87) Predicted to face the ligand binding pocket, Val
2.53
 makes van der Waals interactions with two methyl 
groups of the subtype specific analogue, S-(+)-Norfenfluramine (SNF) 
Val
2.53
Ala mutation decreases SNF binding affinity 190-fold 
Val
2.53
Leu decreases SNF binding affinity 17-fold – MD simulations show a loss of one van der Waals 
interaction between 2.53 and an SNF methyl group owing to the loss of the bulky Val side-chain 
Val
2.53
Ile conservative mutation showed unchanged SNF binding affinity as the bulky side-chain 
maintains interactions with both SNF methyl groups as it does in the wild-type receptor 
 
(Setola et al., 2005) 
Rat urotensin-II Tyr100 SCAM mutation Tyr100Cys had no effect on receptor function, may be part of the ligand binding 
pocket, proposed interaction with 2 antagonists linking Tyr100 to orthosteric binding  
 
(Sainsily et al., 2013) 
Tachykinin NK3 Met(134) Ala mutant showed 53-fold decrease in binding affinity for antagonist, RO5328673 and abolished effect 
of another antagonist 
 
(Malherbe et al., 2014) 
(Malherbe et al., 2008) 
Rhodopsin Met(86) Side-chain movement resulting from a helix bend in TMD2 which is necessary for receptor activation, 
possible water-mediated interaction with Trp
6.48(265) 
 
(Deupi et al., 2012) 
(Deupi, 2014) 
 
Kappa-opioid (KOR) Val(100) Water accessible by SCAM analysis, may modulate orientation of residues within the ligand binding 
pocket to confer subtype selectivity of Salvinorin A for KOR over MOR and DOR 
Contacts the selective antagonist, JDTic  
 
(Vortherms et al., 2007) 
(Wu et al., 2012) 
Delta-opioid (DOR) Ala(98) Water inaccessible by SCAM analysis, may be obscured by large side-chain of a neighbouring residue 
 
(Vortherms et al., 2007) 
Thyroid-stimulating 
hormone (TSHR) 
Met(463) Met
2.53
Val is a naturally-occurring mutant that may cause constitutive activity, mutant receptor 
expression was significantly lower than wildtype, phenotype of non-autoimmune hyperthyroidism due to 
gain-of-function mutation 
 
(Fuhrer et al., 2000) 
 
M1 Muscarinic Ile(74) Ile
2.53
Ala showed reduced signalling capacity, nearly no effect on receptor expression and a small 
decrease in acetylcholine  binding affinity, Ile
2.53 
has a role in G protein coupling  
 
(Bee & Hulme, 2007) 
Table 1.2: Summary of the role of the residue at locus 2.53 in class A GPCRs  
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Dopamine (D2R) Val(83) Val
2.53
Leu showed impaired ligand binding, indicating that valine
2.53 
contributes to recognition of 
Dopamine. This residue may also communicate with Trp
6.48 
via water molecules 
Val
2.53
 is water-accessible by SCAM analysis, placing it within a hydrophilic environment and may 
contact a subtype selective antagonist  
 
(Rodriguez et al., 2010) 
(Javitch et al., 1999) 
Neurokinin-1 (NK1R) Met(81) Met
2.53
 thought to be part of the binding pocket, mutation to Ala showed no change in binding affinity 
for agonist (Substance P) or antagonist (CP-96,345). Not likely to be a ligand contacting residue 
 
(Fong et al., 1994) 
Endothelin A Tyr(129) Mutations of Tyr
2.53
 to Ala, His, Lys, Ser, Gln, Asn and Phe showed changes in affinity for some ligands 
but not others and partially decreased signalling, suggests that Tyr
2.53
 confers subtype selective ligand 
binding  
 
(Lee et al., 1994) (Webb et al., 
1996) (Krystek et al., 1994) 
Mouse GnRHR Glu(90) Mutation of Glu
2.53 
to the isosteric amide, Gln, showed no change in GnRH-stimulated signalling. 
Suggests that Gln can substitute for Glu
2.53 
in the mouse GnRHR 
 
(Flanagan et al., 1994) 
Human GnRHR Glu(90) Mutation of Glu
2.53 
to Ala abolished ligand binding and signalling. Was proposed that Ala caused a 
distortion in the ligand binding pocket or in the overall receptor fold that decreased GnRHR expression 
 
(Hoffmann et al., 2000) 
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2. Chapter 2: Materials and methods 
2.1. Site-directed mutagenesis 
PCR-based whole plasmid site-directed mutagenesis was used to generate mutant 
GnRHRs. Mutagenic primers were designed to substitute Glu
2.53(90) 
with Ala, Arg, Asn, Asp, 
Phe, Gln, Leu, Lys and Ser (table 2.1). Mutating Glu to the small amino acid, Ala, which has 
only a methyl group, effectively removes the side-chain. Mutation to Asp preserves the 
carboxyl group of Glu
2.53(90)
. Asn and Ser have shorter side-chains than Glu and are uncharged 
but can form hydrogen bonds. Gln is isosteric with Glu
2.53(90)
, therefore the side-chain length 
is maintained but Gln has uncharged hydrogen-bonding groups instead of a carboxyl group. 
Whereas, Phe and Leu are similar in size to Glu, they have hydrophobic side-chains that do 
make hydrogen bonds and favor being buried within the protein core. The substitution of Glu 
with Lys replicates the naturally-occurring Glu
2.53(90)
Lys mutant and the introduction of 
positively-charged Lys would be expected to cause a charge repulsion if Glu
2.53(90)
 interacts 
with Lys
3.32(121)
 in the wild type GnRHR. Substitution with Arg introduces a larger positively-
charged side-chain than Lys that would be expected to have a similar effect to that of the Lys 
substitution. All mutagenic primers incorporated unique silent restriction enzyme sites for 
each mutant that allowed for identification of mutant DNA by restriction digest analysis (table 
2.1).  
Wild type human GnRHR cDNA cloned into pcDNA3 (10 ng; Invitrogen, Carlsbad, 
California) was used as template and mixed with mutagenic primers (0.3 µM), 
dimethylsulfoxide (5%), deoxynucleotide triphosphate (dNTP) mix (0.3 mM each dNTP, 
KAPA Biosystems, Cape Town, South Africa) and high fidelity DNA polymerase enzyme 
(0.5 U, KAPA Biosystems) in a final reaction volume of 50 µl of high fidelity PCR buffer 
(KAPA Biosystems). 
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Table 2.1: Primer sequences used to generate mutant GnRH receptors. Wild type GnRH receptor 
sense and antisense cDNA sequences are shown with the Glu
2.53(90)
 codon underlined.  Sequences of 
mutagenic primers are shown with amino acid codons underlined and the silent restriction enzyme 
sites shaded. 
 
 GnRH 
receptor 
construct 
 
Primer Sequences  
Silent 
Restriction 
Enzyme 
Digest 
a
 
Wild type 
 
5’CCTTAGCCAACCTGTTGGAGACTCTGATTGTCATGCC3’ 
3’GGAATCGGTTGGACAACCTCTGAGACTAACAGTACGG5’ 
- - 
Glu
2.53(90)
Ala 5’CCTTAGCCAACCTGTTGGCCACTCTGATTGTCATGCC3’ 
5’GGCATGACAATCAGAGTGGCCAACAGGTTGGCTAAGG3’ 
MscI 
5'TGG↓CC3' 
4363, 2283 
Glu
2.53(90)
Asn 5’CCTTAGCCAACCTGCTGAACACTCTGATTGTCATGCC3’ 
5’GGCATGACAATCAGAGTGTTCAGCAGGTTGGCTAAGG3’ 
 
BveI 
5'ACCTGC(N)4
↓3' 
4893, 922, 
450, 381 
Glu
2.53(90)
Asp 5’CCTTAGCCAACCTTCTAGACACTCTGATTGTCATGCC3’ 
5’GGCATGACAATCAGAGTGTCTAGAAGGTTGGCTAAGG3’ 
XbaI 
5'T↓CTAGA3' 
5726, 920 
Glu
2.53(90)
Phe 5’CCTTAGCCAACCTGCTGTTCACTCTGATTGTCATGCC3’ 
5’GGCATGACAATCAGAGTGAACAGCAGGTTGGCTAAGG3’ 
 
BveI 
5'ACCTGC(N)4
↓3' 
4893, 922, 
450, 381 
Glu
2.53(90)
Gln 5’CCTTAGCCAACCTGCTGCAGACTCTGATTGTCATGCC3’ 
5’GGCATGACAATCAGAGTCTGCAGCAGGTTGGCTAAGG3’ 
 
PstI 
5'CTGCA↓G3' 
4123, 2240, 
283 
Glu
2.53(90)
Leu 5’CCTTAGCCAACCTGCTGTTAACTCTGATTGTCATGCC3’ 
5’GGCATGACAATCAGAGTTAACAGCAGGTTGGCTAAGG3’ 
HpaI 
5'GTT↓AAC3' 
6646  
Glu
2.53(90)
Lys 5’CCTTAGCCAACCTGCTTAAGACTCTGATTGTCATGCC3’ 
5’GGCATGACAATCAGAGTCTTAAGCAGGTTGGCTAAGG3’ 
AflII 
5'C↓TTAAG3' 
3567, 2077, 
1002 
Glu
2.53(90)
Arg 5'CCTTAGCCAACCTGTTGCGCACTCTGATTGTCATGCC3' 
5'GGCATGACAATCAGAGTGCGCAACAGGTTGGCTAAGG3' 
 
NsbI 
5'TGC↓GCA3' 
2361, 2303, 
1982 
Glu
2.53(90)
Ser 5'CCTTAGCCAACCTGCTGTCGACTCTGATTGTCATGCC3' 
5'GGCATGACAATCAGAGTCGACAGCAGGTTGGCTAAGG3' 
 
SalI 
5'G↓TCGAC3' 
3193, 2188, 
1198, 67  
Trp
6.48(280)
Ala 5'TCATTTACTGTCTGCGCAACTCCCtACTATGTC3' 
5'GACATAGTAGGGAGTTGCGCAGACAGTAAATGA3' 
NsbI 
5'TGC↓GCA3' 
2537, 2361, 
1748 
Trp
6.48(280)
Arg 5'TCATTTACTGTCTGCAGAACTCCCTACTATGTC3' 
5'GACATAGTAGGGAGTTCTGCAGACAGTAAATGA3' 
PstI 
5'CTGCA↓G3' 
2523, 1670, 
853 
a
Digest,
 
DNA fragment lengths generated by digestion with specific silent restriction enzymes in the 
presence of the mutation. Except for HpaI, all restriction enzymes digest either the GnRHR gene or 
the vector in addition to the restriction site introduced by the mutation 
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After an initial denaturation step (5 min, 95˚C), DNA was amplified for 16 cycles (98˚C for 
20 seconds, 63˚C for 15 seconds and 72˚C for 7 min) followed by a final extension step (72˚C 
for 5 min) (T100 Thermal Cycler, Biorad, Hercules, California). DpnI restriction 
endonuclease (2 U, Thermo Scientific, Waltham, Massachusetts) was added directly to the 
PCR reaction and incubated (37˚C, overnight). DpnI digests only methylated template DNA, 
while unmethylated mutant PCR products remain intact.  
DpnI-digested PCR products (3 µl) were transformed into competent JM109 E. coli 
cells (100 µl) and cultured on Luria agar plates with ampicillin (1 µg/ml, Sigma Aldrich, Saint 
Louis, Missouri). Colonies were cultured in Luria broth with ampicillin (37˚C, 16 hours) for 
small scale plasmid DNA isolation. Cultures were centrifuged to pellet cells (1500 g, 10 min) 
and dispersed into resuspension buffer (50 mM Tris-HCl, 10 mM ethylenediaminetetraacetic 
acid (EDTA) pH8, 10 mg/ml RNAse A), before mixing with lysis buffer (100 mM NaOH, 
10% sodium dodecyl sulphate (SDS)) to release the DNA. Cell lysates were neutralized (3 M 
potassium acetate, pH 5.5), incubated on ice (5 min) and centrifuged (13500 g, 10 min). 
Supernatants were mixed with silica (5% suspension in water, Sigma Aldrich, Saint Louis, 
Missouri), incubated (5 minutes on ice) and centrifuged (13500 g, 1 min). Supernatants were 
discarded and silica pellets were resuspended in wash buffer (10 mM Tris-HCl pH 8, 100 mM 
NaCl, 2.5 mM EDTA, 55% ethanol) and centrifuged (13500 g, 1 min). DNA was eluted from 
the silica in Tris-EDTA buffer (10 mM Tris-HCl pH 8, 1 mM EDTA) at 55˚C. Restriction 
digest analysis was performed to identify mutant DNA. Mutant constructs were sequenced 
(Inqaba Biotechnologies, Johannesburg, South Africa) to confirm the presence of intended 
mutations and the absence of unintended PCR errors.  
Wild type and mutant receptors were subcloned into the EcoRI and XhoI sites of the 
improved pcDNA3.1+ expression vector (Invitrogen, Carlsbad, California). Subcloning 
served to exclude any PCR errors in the parent vector that might compromise the 
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experimental data. It has previously been found that appending a catfish carboxy-terminal tail 
enhances expression of both wild type and mutant human GnRHRs (Janovick et al., 2003). 
Appending a human type II GnRHR carboxy-terminal has been shown to enhance expression 
of wild type human GnRHRs (Flanagan et al., 2000). Therefore to enhance expression of 
poorly-expressed Glu
2.53(90) 
mutant GnRHRs, these GnRHRs were subcloned into the EcoRI 
and EcoNI sites of a GnRHR construct with a human type II GnRHR carboxy-terminal 
domain (Flanagan et al., 2000) as a means of appending a carboxy-terminal tail. 
The Trp
6.48(280) 
mutant GnRHRs were generated using overlap extension PCR because 
the annealing temperatures of the mutagenic primer pairs for the Trp
6.48(280) 
mutations were 
different, making it nearly impossible to amplify the complementary primers in a single PCR 
reaction. The overlap extension PCR involved three separate rounds of cycling. For each 
Trp
6.48(280)
 GnRHR mutant, two separate PCR reactions were performed with a vector primer 
and the corresponding mutagenic primer (T7 primer and the reverse mutagenic primer = 
PCR1, BGH primer and the forward mutagenic primer = PCR2). Plasmids containing wild 
type human GnRHR cDNA or the wild type GnRHR with the human type II GnRHR 
carboxy-terminal domain were used as templates. Template DNA (10ng) was mixed with 
mutagenic primers (0.3 µM), vector primers (T7 or BGH, 0.3 µM), dimethylsulfoxide (5%), 
dNTP mix (0.3 mM each dNTP) and high fidelity DNA polymerase enzyme (0.5 U) in a final 
reaction volume of 50 µl of high fidelity PCR buffer. After an initial denaturation step (5 min, 
95˚C), DNA was amplified for 30 cycles (98˚C for 20 seconds, 55˚C for PCR1 or 62˚C for 
PCR2 for 15 seconds and 72˚C for 2 min) followed by a final extension step (72˚C for 5 min). 
PCR products were subjected to electrophoresis (1% agarose gel at 65V for 1 hour) and 
extracted from the gel using a gel preparation kit (Favorgen, Biocom Biotech) and used as 
templates for the subsequent overlap PCR reaction.  
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PCR1 extract (3µl) was combined with PCR2 extract (2µl) and mixed with dNTP mix 
(0.3 mM each dNTP) and high fidelity DNA polymerase enzyme (0.5 U), but no primers, in a 
final reaction volume of 20 µl of high fidelity PCR buffer and nuclease-free water. After an 
initial denaturation step (5 min, 94˚C), PCR products were extended for 5 cycles (94˚C for 30 
seconds, 55˚C for 20 min and 72˚C for 2.5 min) and held at 4˚C. Vector primers (T7 and 
BGH, 0.3 µM), dimethylsulfoxide (5%), dNTP mix (0.3 mM each dNTP), high fidelity PCR 
buffer and high fidelity DNA polymerase enzyme (0.5 U) were added to each reaction to give 
a final reaction volume of 25 µl. After an initial denaturation step (30 seconds, 95˚C), DNA 
was amplified for 35 cycles (95˚C for 30 seconds, 50˚C for 30 seconds, 72˚C for 5 min) 
followed by a final extension step (72˚C for 10 min). These PCR products were 
electrophoresed (1% agarose gel at 65V for 1 hour), excised and extracted from the gel to be 
ligated and cloned into the EcoRI and XhoI sites of the pcDNA3.1+vector. This resulted in 
two sets of Trp
6.48(280) 
mutant GnRHRs, with and without a carboxy-terminal tail, depending 
on the template DNA used. All subcloned wild type and mutant receptor DNA constructs 
were then prepared for functional assays by large scale plasmid isolation (PureYield
TM
 
plasmid maxiprep system, Promega, Madison, Wisconsin). 
2.2. Cell culture and transfection 
COS7 cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Biowest, France) supplemented with 10 % foetal bovine serum (FBS, Thermo Scientific, 
Waltham, Massachusetts) and Pen-Strep (0.5mg/ml penicillin, 0.1mg/ml streptomycin) at 
37˚C in 10 % CO2. Wild type and mutant GnRH receptor constructs were transiently 
transfected into COS7 cells, which do not naturally express GnRH receptors. A transfection 
complex was prepared by mixing 5 µg of DNA, 5 µl of Plus Reagent™ and 20 µl of 
Lipofectamine® LTX (Invitrogen, Carlsbad, California) in 500 µl of HEPES (20 mM)-
buffered DMEM (HEPES-DMEM, pH7.4). The transfection complex was incubated at room 
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temperature for 30 minutes and added to COS7 cells in a 100 mm dish containing 4 ml of 
culture medium. Cells were incubated at 37˚C in 10 % CO2 for 24 hours. Transfected cells 
were detached from transfection dishes with PBS-EDTA (10 mM EDTA, 1 x PBS), pelleted 
by centrifugation (500 g, 3 minutes), plated into 12-well plates and cultured overnight (37˚C 
in 10 % CO2). 
2.3. IP accumulation assays 
Production of IP was used to assess the ability of wild type and mutant GnRH 
receptors to mediate GnRH-stimulated signaling essentially as previously described (Millar et 
al, 1995). Transfected cells were radiolabelled with [
3
H]-myoinositol (1 µCi/ml, 1ml/well) 
(Perkin Elmer, Boston, Massachusetts) in DMEM supplemented with FBS (2 %) overnight. 
Labeling medium was aspirated and cells were pre-incubated with pre-warmed buffer I (140 
mM NaCl, 4 mM KCl, 8.6 mM glucose, 1 mM CaCl2, 1 mM MgCl2, 0.1 % bovine serum 
albumin (BSA), 10 mM LiCl, pH 7.4; 1 ml/well, 37˚C, 15 minutes). Cells were stimulated by 
incubation in the absence or presence of various concentrations (10
-11 
M, 10
-10 
M, 10
-9 
M, 10
-8 
M, 10
-7 
M, 10
-6 M) of GnRH (37˚C, 60 min) in buffer I. The incubation was terminated by 
replacing the medium with formic acid (10 mM, 1 ml, 4˚C) and incubation (4˚C, 30 min) to 
lyse the cells. Hypotonic lysis releases the cytoplasmic cellular contents including the 
radiolabeled [
3
H]-IP. Cell extracts were applied to Dowex-1 resin (1 ml; Sigma Aldrich, Saint 
Louis, Missouri) in 10 ml chromatography columns (Biorad, Hercules, California) prewashed 
with 3 M ammonium formate/0.1 M formic acid (3 ml) and distilled water (10 ml). After 
washing with water (10 ml) and 0.1 M formic acid (5 ml), bound [
3
H]-IP was eluted with 1 M 
ammonium formate/0.1M formic acid (3 ml). Eluates were collected in scintillation fluid (3 
ml, Optiphase Hisafe III, Perkin Elmer, Boston, Massachusetts) and counted by liquid 
scintillation spectroscopy (Tri-Cab Liquid Scintillation Analyzer, United Technologies 
Packard, Paolo Alto, California).  
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2.4. Radioligand competition binding assays 
2.4.1. Radio-iodination of [His5,D-Tyr6]-GnRH 
 
The high affinity GnRH analogue, [His
5
,D-Tyr
6
]-GnRH, was radio-labelled and used 
as a tracer in ligand binding assays. The chloramine T iodination method (Flanagan et al, 
1998) was adapted. [His
5
,D-Tyr
6
]-GnRH peptide (5 g) was incubated in NaH2PO4 (0.5 M, 
25 l, pH 7.4) with NaI125 (1 mCi; Perkin Elmer) and chloramine T (10 l, 85 nM in 0.5 M 
NaH2PO4) for 10 seconds. The reaction was stopped by addition of sodium metabisulfite (50 
µl, 85 nM in 0.5 M NaH2PO4). The iodinated peptide was separated from free I
125
 by QAE 
Sephadex purification. QAE Sephadex A25 (Sigma Aldrich, Saint Louis, Missouri) and 
Sephadex G25 (Sigma Aldrich, Saint Louis, Missouri) beads were presoaked in water 
overnight. The top of a 10 ml serological plastic pipette was cut off and the tip was plugged 
with glass wool to act as a disposable chromatography column. The column was prepared by 
pouring and packing ~10 ml of QAE Sephadex A25 suspension followed by ~2 ml of G25 
Sephadex applied on top and was equilibrated with  0.1 M NH4HCO3 to pH 9.2. The 
iodination mixture was applied to the column and eluted with 0.1 M NH4HCO3 (pH 9.2). 1 ml 
fractions of eluate were collected into glass tubes containing 10 µl 10% BSA and 400 µl 0.1 
M acetic acid. 10 µl of these fractions were transferred to 1ml of 0.1 M NH4HCO3 (pH 9.2) 
and 100 µl of these mixtures were counted using a gamma counter (Perkin Elmer, Wizard 2.1 
sample detector). Fractions with highest radioactivity were aliquoted, frozen (-70˚C) and 
tested for specific binding. Fractions with the highest specific binding were used in 
competition binding assays.  
2.4.2. Competition binding assay 
 
Transfected cells were washed with 1 ml cold binding buffer (HEPES-DMEM with 
0.1 % BSA; pH 7.4) and incubated (4˚C, 5 hours) with 125I-[His5,D-Tyr6]-GnRH (~100 000 
cpm) in the absence or presence of various concentrations (10
-10 
M, 10
-9 
M, 10
-8 
M, 10
-7 
M, 
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10
˗6 
M) of unlabelled GnRH or unlabelled [His
5
,D-Tyr
6
]-GnRH for homologous competition 
in a final volume of 500µl binding buffer. The incubation was terminated by washing 3 times 
with cold PBS to remove unbound radioligand and bound radioligand was collected from 
plates by solubilization of cells with 0.1 M NaOH (1 ml/ well). The radioactivity was counted 
in a gamma counter. 
2.5. Data analysis 
IP production and radioligand binding assays were performed at least 3 times in 
duplicate for each GnRHR mutant and the wild type GnRHR was included in every assay. For 
the IP assays, maximal response (Emax) and effective concentrations for 50% of maximal 
response (EC50) were determined from sigmoidal dose-response curves fitted to experimental 
data sets using non-linear regression (GraphPad Prism software, version 5, La Jolla, 
California). Similarly, total binding in the absence of unlabelled ligand (B0) and 50% 
inhibitory concentrations (IC50) for radioligand binding assays were determined using non-
linear regression. pEC50 and pIC50 values were calculated as negative logarithms of EC50 and 
IC50 values respectively. This transformed the mean ± SD data to a normal distribution that 
could be used for group comparison statistical analysis (Flanagan, 2016). A one-way analysis 
of variance with post-hoc Tukey’s test was used to determine whether pEC50 and pIC50 values 
for each mutant GnRHR differed from the values of the wild type GnRHRs.  
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3. Chapter 3: Results 
3.1. Confirmation that the naturally-occurring Glu2.53(90)Lys mutant GnRHR is non-
functional  
COS7 cells transfected with wild type human GnRHR showed robust GnRH-stimulated IP 
production with an EC50 value of 0.26 ± 0.31nM, whereas vector-transfected cells showed no 
IP response to GnRH stimulation (figure 3.1, table 3.1). This result confirms expression of the 
wild type human GnRHR in COS7 cells and coupling of the receptor to IP signalling. In 
contrast, COS7 cells transfected with the Glu
2.53(90)
Lys mutant GnRHR showed no detectable 
GnRH-stimulated IP production (figure 3.1, table 3.1). Consistent with the signalling results, 
the wild type GnRHR displayed high total ligand binding (figure 3.1, table 3.1), and the 
Glu
2.53(90)
Lys mutant GnRHR showed no detectable binding. The lack of detectable binding 
indicates minimal cell surface expression of the Glu
2.53(90)
Lys mutant GnRHR. 
 
 
 
 
 
 
 
Figure 3.1: GnRH-stimulated IP accumulation and competition binding in COS7 cells expressing wild 
type and Glu
2.53(90)
Lys GnRHRs. COS7 cells transfected with wild type (WT, ●), Glu2.53(90)Lys (E90K, ▲), 
tailed wild type (WT-CT, ○) or tailed Glu2.53(90)Lys (E90K-CT, ∆) GnRHRs were treated with increasing 
concentrations of GnRH before IP extraction (Left panel) or cells were incubated with 
125
I-[His
5
,D-Tyr
6
]-GnRH 
in the presence of increasing concentrations of GnRH and bound radioactivity was counted (Right panel). ‘B’ 
represents basal IP production in the absence of ligand.‘B0’ represents total binding in the absence of unlabelled 
or competing ligand. Data are from a single experiment, representative of experiments that were performed at 
least three times in duplicate.  
3.2. Rescue of Glu2.53(90)Lys mutant GnRHR expression and function by appending the 
Type II GnRHR carboxy-terminal tail  
Appending the human Type II GnRHR carboxy-terminal tail to the wild type GnRHR (see 
methods) increased the maximum GnRH-stimulated IP production in most experiments, but 
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had no significant effect on GnRH potency (EC50, 0.21 ± 0.25 nM vs 0.26 ± 0.31 nM for the 
untailed wild type GnRHR, figure 3.1, table 3.1). Appending the carboxy-terminal tail to the 
wild type GnRHR increased total binding of I
125
-[His
5
,D-Tyr
6
]-GnRH (figure 3.1) without 
changing affinity for GnRH (IC50, 4.76 ± 1.35 nM vs 3.33 ± 1.26 nM for the untailed wild 
type GnRHR, figure 3.1, table 3.1). This is consistent with enhanced receptor expression as 
previously described (Flanagan et al., 2000). Similar findings were reported when the 
carboxy-terminal tail of a catfish GnRHR was appended to wild type and several mutant 
GnRHRs (Janovick et al., 2003). COS7 cells expressing the Glu
2.53(90)
Lys mutant GnRHR 
with the carboxy-tail showed detectable binding of I
125
-[His
5
,D-Tyr
6
]-GnRH and GnRH-
stimulated IP production similar to levels of the untailed wild type GnRHR (figure 3.1, table 
3.1), which is consistent with enhanced expression and functional rescue of this mutant 
receptor as previously described (Flanagan et al., 2000; Janovick et al., 2009; Maya-Nu´nez et 
al., 2002). The affinity of the rescued Glu
2.53(90)
Lys mutant GnRHR with the carboxy-tail was 
unchanged from wild type (IC50, 3.2 ± 0.05 nM vs 3.3 ± 1.26 nM for the untailed wild type 
GnRHR, figure 3.1, table 3.1), as previously described (Tello et al., 2012; Söderlund et al., 
2001). 
3.3. IP signalling and ligand binding of mutant GnRHRs with small amino acid 
substitutions for Glu
2.53(90) 
 
COS7 cells expressing mutant GnRHRs in which Glu
2.53(90) 
was
 
substituted with Ala, Ser and 
Asn showed no detectable GnRH-stimulated IP production (Figure 3.2, table 3.1) and no 
detectable 
125
I-[His
5
,D-Tyr
6
]-GnRH binding (figure 3.2, table 3.1). The mutant receptor with 
the conservative, acidic, Asp substitution for Glu
2.53(90)
 also showed no detectable GnRH-
stimulated IP production (figure 3.2, table 3.1) and no detectable 
125
I-[His
5
,D-Tyr
6
]-GnRH 
binding (figure 3.2, table 3.1). This indicates that the negatively-charged carboxyl group of 
the Asp sidechain is not sufficient to substitute for the native Glu
2.53(90) 
in expression of the 
GnRHR. Appending the carboxy-tail to the Glu
2.53(90)
Ala mutant GnRHR resulted in 
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measurable IP production and binding (Emax, 35 ± 15 % and B0, 38 ± 7 % of untailed wildtype 
GnRHR, figure 3.2, table 3.1). Potency was not different from the untailed wildtype GnRHR 
(EC50, 0.10 ± 0.09 nM vs 0.26 ± 0.31 nM for the untailed wild type GnRHR, figure 3.2, table 
3.1), but affinity of the tailed Glu
2.53(90)
Ala mutant GnRHR was reduced (IC50, 19.95 ± 0.01 
nM vs 3.33 ± 1.26 nM for the untailed wild type GnRHR, figure 3.2, table 3.1). In contrast, 
the Glu
2.53(90)
Ser, Glu
2.53(90)
Asn and Glu
2.53(90)
Asp mutant GnRHRs with carboxy-tails showed 
no measurable IP production or total 
125
I-[His
5
,D-Tyr
6
]-GnRH binding (figure 3.2, table 3.1). 
The addition of the carboxy-terminal tail rescued expression of the Glu
2.53(90)
Ala mutant 
GnRHR but not the expression of mutant GnRHRs with small and polar side-chains, 
suggesting that these mutations may introduce destabilizing interactions that cannot be 
overcome by the carboxy-terminal tail. 
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Table 3.1: GnRH-stimulated IP production and competition binding of COS7 cells transfected with wild type and mutant GnRHRs. Data are means ± SD of the 
indicated numbers of experiments performed in duplicate. All experiments included the wild type GnRHR and tailed wild type GnRHR. 
*Significantly different from wild type GnRHR 
p<0.05; 
a
-CT, Carboxy terminal-tail appended 
b
nms, no measurable stimulation 
c
nmb, no measurable binding
 
GnRH Receptor 
IP Production   Competition Binding 
EC50 (nM) pEC50  Emax(%WT)  IC50 (nM) pIC50  B0 (%WT) 
        
Wild type  0.26 ± 0.31 9.58 ± 0.64 (n=19) 100  3.33 ± 1.26 8.59 ± 0.26 (n=13) 100 
Wild type-CT
a 
0.21 ± 0.25  9.89 ± 0.41 (n=17) 146 ± 43  4.76 ± 1.35 8.34 ± 0.14 (n=13) 200 ± 61 
Glu
2.53(90)
Lys -  - (n=3) nmsb  - - (n=3) nmbc
 
Glu
2.53(90)
Lys-CT 0.14 ± 0.14  9.97 ± 0.15 (n=3) 132 ± 48  3.2 ± 0.05 8.50 ± 0.01 (n=3) 185 ± 35 
Glu
2.53(90)
Ala -  - (n=4) nms  - - (n=4) nmb 
Glu
2.53(90)
Ala-CT   0.10 ± 0.09  9.80 ± 0.20 (n=3) 35 ± 15  19.95 ± 0.01 7.70 ± 0.3* (n=3) 38 ± 7 
Glu
2.53(90)
Asp - - (n=4) nms  - - (n=4) nmb 
Glu
2.53(90)
Asp-CT - - (n=4) nms  - - (n=4) nmb 
Glu
2.53(90)
Ser - - (n=3) nms  - - (n=3) nmb 
Glu
2.53(90)
Ser-CT   - - (n=3) nms  - - (n=3) nmb 
Glu
2.53(90)
Asn  - - (n=3) nms  - - (n=3) nmb 
Glu
2.53(90)
Asn-CT - - (n=3) nms  - - (n=5) nmb 
Glu
2.53(90)
Gln  0.23 ± 0.06 9.70 ± 0.1 (n=3) 84 ± 18  5.04 ± 2.19 8.33 ± 0.28 (n=3) 58 ± 21 
Glu
2.53(90)
Gln-CT 0.27 ± 0.31 9.80 ± 0.56 (n=3) 148 ± 106  3.34 ± 1.44 8.5 ± 0.21 (n=3) 107 ± 10 
Glu
2.53(90)
Phe  0.27 ± 0.12 9.51 ± 0.15 (n=3) 110 ± 51  2.97 ± 0.40 8.53 ± 0.10 (n=3) 76 ± 4 
Glu
2.53(90)
Phe-CT 0.30 ± 0.20 9.63 ± 0.35 (n=3) 160 ± 34  2.99 ± 0.51 8.50 ± 0.15 (n=3) 252 ±2 9 
Glu
2.53(90)
Leu 0.19 ± 0.21 9.70 ± 0.35 (n=6) 100 ± 34  4.39 ± 1.07 8.37 ± 0.11 (n=6) 108 ± 85 
Glu
2.53(90)
Leu-CT 0.23 ± 0.24 10.0 ± 0.61 (n=3) 119 ± 7  2.83 ± 1.03 8.50 ± 0.10 (n=3) 119 ± 20 
Glu
2.53(90)
Arg  80.3 ± 7.60 7.13 ± 0.60* (n=6) 64 ± 26  82.1 ± 0.09 7.08 ± 0.17* (n=6) 25 ± 8 
Glu
2.53(90)
Arg-CT 7.47 ± 7.39 8.27 ± 0.40* (n=7) 121 ± 70  79.4 ± 0.02 7.10 ± 0.02* (n=7) 58 ± 4 
Trp
6.48(280)
Ala  - - (n=8) nms  - - (n=8) nmb 
Trp
6.48(280)
Ala-CT 0.21 ± 0.14 9.82 ± 0.33 (n=5) 80 ± 18  4.39 ± 1.07 8.43 ± 0.12 (n=5) 96 ± 13 
Trp
6.48(280)
Arg  - - (n=6) nms  - - (n=6) nmb 
Trp
6.48(280)
Arg-CT 53.3 ± 46.9 7.40 ± 0.37* (n=7) 64 ± 15  27.73 ± 6.74 7.57 ± 0.11* (n=7) 97 ± 30 
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Figure 3.2: GnRH-stimulated IP accumulation and competition binding in COS7 cells expressing mutant 
GnRHRs with small amino acid substitutions for Glu
2.53(90)
. COS7 cells transfected with wild type (WT, ●), 
tailed wild type (WT-CT, ○), Glu2.53(90)Ala (E90A, x), tailed Glu2.53(90)Ala (E90A-CT, +), Glu2.53(90)Asp (E90D, 
■), tailed Glu2.53(90)Asp (E90D-CT, □), Glu2.53(90)Asn (E90N, ♦), tailed Glu2.53(90)Asn (E90N-CT, ◊),Glu2.53(90)Ser 
(E90S, ▲) or tailed Glu2.53(90)Ser (E90S-CT, ∆) GnRHRs were treated with increasing concentrations of GnRH 
before IP extraction (Left panel) or cells were incubated with 
125
I-[His
5
,D-Tyr
6
]-GnRH in the presence of 
increasing concentrations of GnRH and bound radioactivity was counted (Right panel). Data are from a single 
experiment, representative of experiments that were performed at least three times in duplicate. 
 
3.4. IP signalling and ligand binding of mutant GnRHRs with large, uncharged amino 
acid substitutions for Glu
2.53(90) 
 
COS7 cells expressing mutant GnRHR in which Glu
2.53(90) 
was substituted with the isosteric 
Gln residue showed GnRH-stimulated IP production with similar potency to that of the wild 
type GnRHR (EC50, 0.23 ± 0.06 nM vs 0.26 ± 0.31 nM for the wild type GnRHR, figure 3.3, 
table 3.1) and bound 125I-[His5,D-Tyr6]-GnRH without any change in affinity (IC50, 5.04 ± 
2.19 nM vs 3.33 ± 1.26 nM for the wild type GnRHR, figure 3.3, table 3.1). This is consistent 
with previously reported function of the Glu
2.53(90)
Gln mouse GnRHR (Flanagan et al. 1994). 
The isosteric Gln differs from Glu only in having an amide (CONH2) rather than a carboxyl 
group (COO
-
)
 
in its sidechain. The unchanged function of the Glu
2.53(90)
Gln mutant GnRHR 
suggests that the negative charge of the Glu
2.53(90) 
is not necessary for GnRHR expression or 
function. COS7 cells expressing the Glu
2.53(90)
Gln mutant GnRHR with the carboxy-terminal 
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tail showed minimal change to maximum IP production and total 
125
I-[His
5
,D-Tyr
6
]-GnRH 
binding compared with the untailed mutant GnRHR (figure 3.3, table 3.1).  
COS7 cells expressing mutant GnRHRs in which Glu
2.53(90) 
was substituted with the large 
hydrophobic Phe or Leu residues showed GnRH-stimulated IP production with Emax values 
similar to wildtype (figure 3.4, table 3.1). GnRH potency and receptor affinity for GnRH 
remained unchanged (figure 3.4, table 3.1). This suggests that the hydrophilic properties of 
the native Glu
2.53(90) 
sidechain might not be necessary for GnRHR expression or function. The 
Glu
2.53(90)
Phe and Glu
2.53(90)
Leu GnRHRs with the carboxy-terminal tail showed increased 
maximum GnRH-stimulated IP production (Emax, 160 ± 34 % and 119 ± 7 % of the untailed 
wild type GnRHR, figure 3.4, table 3.1). The Glu
2.53(90)
Phe GnRHR with the carboxy-terminal 
tail showed increased total binding of 
125
I-[His
5
,D-Tyr
6
]-GnRH (B0, 252 ± 29 % of the 
untailed wild type GnRHR, figure 3.4, table 3.1). Both of these mutant GnRHRs showed 
unchanged affinities for GnRH. 
 
 
 
 
 
Figure 3.3: GnRH-stimulated IP accumulation and competition binding in COS7 cells expressing mutant 
GnRHRs with Gln substituted for Glu
2.53(90)
. COS7 cells transfected with wild type (WT, ●), tailed wild type 
(WT-CT, ○), Glu2.53(90)Gln (E90Q, ▲) or tailed Glu2.53(90)Gln (E90Q-CT, ∆) GnRHRs were (Left panel) treated 
with increasing concentrations of GnRH before IP extraction or (Right panel) were incubated with 
125
I-[His
5
,D-
Tyr
6
]-GnRH in the presence of increasing concentrations of GnRH and bound radioactivity was counted. Data 
are from a single experiment, representative of experiments that were performed at least three times in duplicate.  
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Figure 3.4: GnRH-stimulated IP accumulation and competition binding in COS7 cells expressing mutant 
GnRHRs with large and hydrophobic amino acid substitutions for Glu
2.53(90)
. COS7 cells transfected with 
wild type (WT, ●), tailed wild type (WT-CT, ○), Glu2.53(90)Leu (E90L, ■) or tailed Glu2.53(90)Leu (E90L-CT, □), 
Glu
2.53(90)
Phe (E90F, ▲) or tailed Glu2.53(90)Phe (E90F-CT, ∆) GnRHRs were (Left panel) treated with increasing 
concentrations of GnRH before IP extraction or (Right panel) were incubated with 
125
I-[His
5
,D-Tyr
6
]-GnRH in 
the presence of increasing concentrations of GnRH and bound radioactivity was counted. Data are from a single 
experiment, representative of experiments that were performed at least three times. 
 
3.5. IP signalling and ligand binding of mutant GnRHRs with a positively charged 
amino acid substitution for Glu
2.53(90) 
 
The sidechain of Arg is basic, like that of Lys of the HH-associated and non-functional 
Glu
2.53(90)
Lys mutant GnRHR. Several authors have modelled an interhelical salt-bridge 
between the native, acidic, Glu
2.53(90)
 and Lys
3.32(121) 
of TM3 (Stewart et al., 2012; Janovick et 
al., 2009). The Arg sidechain is longer than Lys and contributes a positive charge owing to a 
guanidinium group on its sidechain (Hoffmann et al., 2000). If a salt-bridge were important 
for GnRHR folding, it would be expected that an Arg substitution for Glu
2.53(90) 
 would disrupt 
expression giving rise to a receptor that behaves similarly to the non-functional Glu
2.53(90)
Lys 
mutant GnRHR. COS7 cells transfected with the Glu
2.53(90)
Arg mutant GnRHR showed 
GnRH-stimulated IP production with a maximum that was similar to the untailed wild type 
GnRHR (Emax, 64 ± 24 % of the untailed wild type GnRHR, figure 3.5, table 3.1). However, 
GnRH potency was significantly decreased (EC50, 80.3 ± 7.6 nM, figure 3.5, table 3.1) 
compared with the untailed wild type GnRHR (0.26 ± 0.31 nM, figure 3.5, table 3.1). The 
Glu
2.53(90)
Arg mutant GnRHR with the carboxy-terminal tail showed measurable IP 
production with decreased potency like its untailed counterpart (EC50, 7.47 ± 7.39 nM, figure 
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3.5, table 3.1). The decreased potency of the Glu
2.53(90)
Arg mutant receptors compared with 
wild type may be a result of partial uncoupling from the IP signalling pathway or decreased 
binding affinity for GnRH. The Glu
2.53(90)
Arg mutant GnRHR showed decreased total binding 
of 
125
I-[His
5
,D-Tyr
6
]-GnRH and a decreased affinity for GnRH (IC50, 82.1 ± 0.09 nM) 
compared with the wild type receptor (3.33 ± 1.26 nM, figure 3.5, table 3.1). The 
Glu
2.53(90)
Arg mutant GnRHR with the carboxy-terminal tail also showed decreased total 
binding of 
125
I-[His
5
,D-Tyr
6
]-GnRH and a decreased affinity for GnRH (IC50, 79.4 ± 0.02 nM, 
figure 3.5, table 3.1) compared with the wild type receptor. The Glu
2.53(90)
Arg mutant 
GnRHRs showed no change in affinity for the high affinity analogue [His
5
,D-Tyr
6
]-GnRH 
(IC50, 3.21 ± 1.34 nM and 4.96 ± 1.15 nM) compared with the untailed wild type GnRHR 
(2.43 ± 0.95 nM, figure 3.5, table 3.1). This unchanged affinity for the constrained GnRH 
analogue explains why the mutant receptor showed measurable binding of 
125
I-[His
5
,D-Tyr
6
]-
GnRH in spite of decreased affinity for GnRH. 
 
 
 
 
Figure 3.5: GnRH-stimulated IP accumulation and competition binding of wild type and Glu
2.53(90)
Arg 
GnRHRs. COS7 cells transfected with wild type (WT, ●), tailed wild type (WT-CT, ○), pcDNA3.1+ vector 
(vector, *), Glu
2.53(90)
Arg (E90R, ♦) or tailed Glu2.53(90)Arg (E90R-CT, ◊).GnRHRs GnRHRs were (Left panel) 
treated with increasing concentrations of GnRH before IP extraction or (Right panel) were incubated with 
125
I-
[His
5
,D-Tyr
6
]-GnRH in the presence of increasing concentrations of GnRH and bound radioactivity was counted. 
Data are from a single experiment, representative of experiments that were performed at least three times in 
duplicate. 
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3.6. IP signalling and ligand binding of mutant GnRHRs with Ala and Arg substitutions 
for Trp
(6.48)280
 
Trp
6.48 
is a highly conserved residue among GPCRs forming part of the CWxPY motif in 
TM6. As discussed in the introduction, it has been suggested that an interaction between 
Trp
6.48
 and the residue at position 2.53 may regulate receptor activation in rhodopsin and 
rhodopsin-like GPCRs (Deupi, 2014; Deupi et al., 2012). To investigate a possible interaction 
in the GnRHR, we mutated the Trp
(6.48)280 
residue to Ala and Arg.  
COS7 cells transfected with the Trp
6.48(280)
Ala mutant GnRHR showed no detectable GnRH-
stimulated IP production and no detectable binding of 
125
I-[His
5
,D-Tyr
6
]-GnRH (Figure 3.6, 
table 3.1). The Trp
6.48(280)
Ala mutant with the carboxy-terminal tail showed IP production 
similar to wild type levels (Emax, 80 ± 18 % of untailed wild type GnRHR, figure 3.6, table 
3.1) and GnRH potency was similar (figure 3.6, table 3.1). This is consistent with a previous 
report of unchanged pharmacology of this mutant receptor when rescued by pre-treatment 
with small molecule antagonist, IN3 (Coetsee et al., 2006). The tailed Trp
6.48(280)
Ala mutant 
showed binding of 
125
I-[His
5
,D-Tyr
6
]-GnRH similar to that of the untailed wild type GnRHR. 
This mutant GnRHR behaved similarly to the Glu
2.53(90)
Lys mutant GnRHR in that appending 
the carboxy-terminal tail rescued receptor function from non-functional to wild type levels, 
with unchanged GnRH potency and unchanged affinity for GnRH. We hypothesized that if 
the Glu
2.53(90) 
and the Trp
6.48(280) 
side-chains are oriented towards each other within the TM 
bundle, substitution of Trp
6.48(280) 
with Arg might result in similar distortion of GnRHR 
function as found for the Glu
2.53(90)
Arg mutant GnRHR. The Trp
6.48(280)
Arg mutant GnRHR 
showed no detectable IP production or binding of 
125
I-[His
5
,D-Tyr
6
]-GnRH (figure 3.6, table 
3.1). However, similar to the Glu
2.53(90)
Arg mutant, the Trp
6.48(280)
Arg mutant GnRHR with the 
carboxy-terminal tail showed GnRH-stimulated IP production with decreased GnRH potency 
(EC50, 53.3 ± 46.9* nM) compared with the wild type GnRHR (0.26 ± 0.31 nM, figure 3.6, 
table 3.1). The tailed Trp
6.48(280)
Arg mutant GnRHR showed binding of 
125
I-[His
5
,D-Tyr
6
]-
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GnRH that was similar to levels of the untailed wild type GnRHR (B0, 97 ± 30 % of untailed 
wild type GnRHR, figure 3.6, table 3.1). Also, similar to the Glu
2.53(90)
Arg mutant, the tailed 
Trp
6.48(280)
Arg mutant GnRHR showed decreased affinity for GnRH (IC50, 27.7 ± 6.74 nM) 
compared with the wild type GnRHR (3.33 ± 1.26 nM, figure 3.6, table 3.1). Thus, the 
decreased potency may be explained by the lower affinity of GnRH for this tailed 
Trp
6.48(280)
Arg mutant GnRHR. The tailed Trp
6.48(280)
 mutant GnRHRs showed no change in 
affinity for the high affinity analogue [His
5
,D-Tyr
6
]-GnRH (IC50, 3.37 ± 0.32 nM for the 
tailed Trp
6.48(280)
Ala mutant GnRHR and 1.76 ± 1.74 nM for the tailed Trp
6.48(280)
Arg mutant 
GnRHR vs 2.43 ± 0.95 nM for the untailed wild type GnRHR). This unchanged affinity 
explains why the mutant receptor showed measurable binding of 
125
I-[His
5
,D-Tyr
6
]-GnRH. 
 
 
 
 
 
 
 
Figure 3.6: GnRH-stimulated IP accumulation and competition binding of wild type, Trp
(6.48)280
Ala 
and Trp
(6.48)280
Arg mutant GnRHRs. COS7 cells transfected with wild type (WT, ●), tailed wild type 
(WT-CT, ○),Trp6.48(280)Ala (W280A, ▲), tailed Trp6.48(280)Ala (W280A-CT, ∆), Trp6.48(280)Arg (W280R, ■) or 
tailed Trp
6.48(280)
Arg (W280R-CT, □) GnRHRs were (Left panel) treated with increasing concentrations of GnRH 
before IP extraction or (Right panel) were incubated with 
125
I-[His
5
,D-Tyr
6
]-GnRH in the presence of increasing 
concentrations of GnRH and bound radioactivity was counted. Data are from a single experiment, representative 
of experiments that were performed at least three times in duplicate.  
 
3.7. Summary of results  
We have confirmed that the Glu
2.53(90)
Lys mutation disrupts GnRHR signalling and ligand 
binding and shown that its function can be recovered to wild type levels by appending the 
Type II GnRHR carboxy-terminal tail. Mutation of Glu
2.53(90) 
to smaller amino acids, 
including the conservative Glu-to-Asp mutant, also disrupted GnRHR function. However, 
addition of the carboxy-terminal tail to these mutant receptor constructs could only recover 
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function of the Glu
2.53(90)
Ala mutant. In contrast, mutant GnRHRs with large uncharged and 
hydrophobic substitutions for Glu
2.53(90) 
retained full wild type-like GnRHR function. The 
Glu
2.53(90)
Arg mutant GnRHR showed robust IP production and binding of radiolabelled 
GnRH agonist, but GnRH affinity and potency were decreased. We have shown that in 
contrast to the Trp
6.48(280)
Ala mutant GnRHR, the Trp
6.48(280)
Arg GnRHR that was recovered 
by appending a carboxy-terminal tail showed decreased affinity for GnRH, similar to that of 
the Glu
2.53(90)
Arg mutant GnRHR. Our results show that the GnRHR is fully functional with 
residues at the 2.53(90) locus that cannot form a salt-bridge with Lys
3.32(121)
 and suggest that 
the size of the Glu
2.53(90) 
side-chain may be important for stabilizing the structure of the 
GnRHR. 
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4. Chapter 4: Discussion 
We have investigated the role of the Glu
2.53(90) 
residue in GnRHR signalling and ligand 
binding. We have confirmed that the Glu
2.53(90)
Lys mutant GnRHR is non-functional, but 
show that function can be recovered by addition of the carboxy-terminal tail of the human 
type II GnRHR. As expected, the recovered Glu
2.53(90)
Lys mutant GnRHR exhibited GnRH-
stimulated IP production and GnRH binding affinity that was indistinguishable from that of 
the wild type GnRHR. The Glu
2.53(90)
Ala mutation, which removes the carboxyl side-chain of 
Glu
2.53(90) 
and introduces only a methyl group, abolished GnRHR function, which was only 
partially recovered by addition of the carboxy-terminal (maximal IP 35% of wild type), 
showing that the Ala substitution is more disruptive than the large, positively-charged Lys 
substitution. Substitution of Glu
2.53(90) 
with small hydrophilic amino acids (Asn, Ser) or with 
the conservative carboxylic Asp resulted in no measurable GnRHR function in the presence or 
absence of a carboxy-terminal tail, showing that these substitutions are more disruptive to the 
GnRHR than either the Ala or the Lys substitutions. The unrecoverable function of the 
Glu
2.53(90)
Asp GnRHR shows that a carboxyl group at the 2.53 locus is not sufficient for 
GnRHR function. A mutant GnRHR with isosteric Gln substituted for Glu
2.53(90) 
showed wild 
type-like activity even in the absence of a carboxy-terminal tail, showing that a negative 
charge is not needed at the 2.53 locus for GnRHR function. This was further supported by the 
wild type-like activities of mutant GnRHRs with large hydrophobic (Phe, Leu) substitutions 
for Glu
2.53(90)
. The unchanged GnRH binding affinities of these mutants and of the recovered 
Glu
2.53(90)
Lys GnRHR show that the residue at the 2.53 locus is not directly involved in ligand 
binding. The unchanged expression (as assessed by total binding in the absence of an 
unlabelled competitor, B0) of GnRHRs with hydrophobic substitutions for Glu
2.53(90) 
indicates 
that an interaction of the Glu
2.53(90) 
side-chain with a basic side-chain is not important for 
GnRHR expression. To test this, we substituted Glu
2.53(90) 
with Arg. High maximal IP 
signalling of the Glu
2.53(90)
Arg mutant GnRHR shows that the mutant was well-expressed. The 
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good expression shows that the Arg at the 2.53 locus is unlikely to be closely apposed to the 
Lys
3.32(121)
 and suggests that the Glu
2.53(90)
 of the wild type GnRHR probably also is not in 
close proximity to the Lys
3.32(121) 
and thus does not form a salt-bridge interaction. 
Nevertheless, the decreased GnRH binding affinity at the Glu
2.53(90)
Arg GnRHR suggests that 
the Glu
2.53(90) 
side-chain makes a non-salt-bridge interaction that configures the ligand binding 
pocket and thus contributes to GnRHR structure. Based on proposals that the residue at the 
2.53 locus of other GPCRs may interact with the conserved Trp
6.48 
via the conserved water-
mediated hydrogen bond network, we mutated Trp
6.48(280) 
of the GnRHR. The wild type-like 
potency and affinity of GnRH at the Trp
6.48(280)
Ala GnRHR with an appended carboxy-
terminal tail shows that Trp
6.48(280) 
is not directly involved in ligand binding, but
 
may have a 
role in GnRHR folding and expression. The decreased GnRH potency and affinity at the 
recovered Trp
6.48(280)
Arg mutant GnRHR suggests that the introduction of the Arg disrupts the 
configuration of the ligand binding pocket and that Trp
6.48(280) 
makes intramolecular 
interactions that affect the structure of the ligand binding pocket. Thus, both Glu
2.53(90)
 and 
Trp
6.48(280) 
have roles in stable folding and expression of the GnRHR and both contribute to 
the structural configuration of the GnRH binding pocket. Based on comparisons with other 
GPCRs, it is likely that Glu
2.53(90)
 and Trp
6.48(280) 
configure the structure of the GnRH binding 
pocket via interactions with the adjacent residues Ser
3.35(124)
 and Met
3.36(125)
 in TM3 of the 
GnRHR. 
4.1. The COOH group of the Glu2.53(90) is not sufficient for GnRHR expression and 
function 
We show that appending the human type II GnRHR carboxy-terminal tail recovers 
function of the Glu
2.53(90)
Lys mutant GnRHR, as did appending the catfish carboxy-terminal 
tail or incubation with small molecule antagonists or pharmacoperones in other studies (Lin et 
al., 1998; Conn & Janovick 2009; Tan et al., 2004, Conn & Janovick 2010). The 
pharmacoperones are said to bind to misfolded proteins, acting as folding templates to 
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stabilize the receptor for trafficking and cell surface expression as opposed to being targeted 
for degradation (Janovick et al., 2009). Therefore, it is likely that the appended carboxy-
terminal tail stabilizes GnRHR expression by enhancing trafficking to the cell surface and 
anchoring the receptor at the cell membrane by similar mechanisms as appending a catfish 
carboxy-terminal tail (Maya-Núñez et al., 2011). The wild type-like GnRH affinity of the 
recovered Glu
2.53(90)
Lys GnRHR indicates that Glu
2.53(90) 
does not directly interact with the 
ligand, but has a structural role in GnRHR folding.  
Substitution of Glu
2.53(90) 
with the small amino acid, Ala, abolished both GnRHR 
signalling and ligand binding. The null mutation shows that some aspect of the Glu
2.53(90) 
side-
chain is necessary for GnRHR expression or function. Our result is consistent with a previous 
report (Hoffmann et al., 2000), which went on to propose that the Glu
2.53(90)
Ala
 
GnRHR was 
non-functional because the Ala substitution disrupted a proposed salt-bridge between 
Glu
2.53(90) 
and Lys
3.32(121) 
residue in TM3. Adding a carboxy-terminal tail to the Glu
2.53(90)
Ala 
mutant GnRHR only partially recovered IP signalling, showing that the stabilization provided 
by the carboxy-terminal tail only partially compensates for the disruptive effect of the Ala 
substitution. Decreased GnRH binding affinity suggests that the Ala substitution causes a 
change in the GnRHR structure that distorts its extracellular surface where the ligand binds.  
Since Asp has a side-chain that is very similar to that of Glu
2.53(90)
, except that it is 
shorter by one CH2 moiety,
 
it is expected that the Glu
2.53(90)
Asp GnRHR would be functional 
owing to the preserved carboxylic group if Glu
2.53(90) 
does make a salt-bridge with Lys
3.32(121)
. 
In contrast, substitution of Glu
2.53(90) 
with Asp also abolished GnRHR signalling and ligand 
binding. Unlike the Glu
2.53(90)
Lys and Glu
2.53(90)
Ala GnRHRs, function of the Glu
2.53(90)
Asp 
GnRHR could not be recovered by addition of a carboxy-terminal tail. This shows that the 
carboxylic group is not sufficient to preserve GnRHR function, but also shows that mis-
positioning of the carboxylic group disrupts GnRHR structure more than Ala, which cannot 
make hydrogen bonds.  
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Mutant GnRHRs with uncharged, small hydrophilic (Asn, Ser) substitutions for 
Glu
2.53(90)
 behaved similarly to the Glu
2.53(90)
Asp GnRHR, in that these mutant GnRHRs 
exhibited no measurable IP signalling or ligand binding and could not be recovered by 
addition of a carboxy-terminal tail. This suggests unfavourable hydrogen bond interactions 
that favour misfolding of the GnRHR and direct mutant receptors to degradation, rather than 
allowing cell surface expression. Since both IP signalling and ligand binding assays depend 
on binding of GnRH agonist to the GnRHR, it is possible that these mutant GnRHRs are 
expressed on the cell surface but are undetectable due to lack of GnRH binding. 
4.2. Large, uncharged and hydrophobic amino acid substitutions stabilize GnRHR 
function 
The substitution of isosteric uncharged Gln for Glu
2.53(90) 
preserves GnRHR expression 
and function, with ligand binding and signalling that is indistinguishable from the wild type 
GnRHR. This shows that charge is unnecessary and suggests to us that Glu
2.53(90) 
may be 
protonated and thus uncharged within the GnRHR TM bundle. Hoffmann et al. (2000) 
proposed that the preservation of wild type-like behaviour in the Glu
2.53(90)
Gln mouse GnRHR 
(Flanagan et al., 1994) may have been a result of Gln making hydrogen bonds with Lys
3.32(121) 
of TM3 that could substitute for the proposed salt-bridge interaction. However, our mutations 
of Glu
2.53(90) 
to large and hydrophobic amino acids (Phe, Leu), which cannot make hydrogen 
bonds, also preserve GnRHR expression and function, with ligand binding and signalling that 
is indistinguishable from the wild type GnRHR. This shows that the hydrophilic properties of 
the Glu
2.53(90) 
side-chain are not necessary for GnRHR expression and function. If it is not the 
carboxylic group or the hydrogen bonding capacity of the Glu
2.53(90) 
that is needed for GnRHR 
expression and function, then perhaps the size or side-chain length of Glu
2.53(90) 
is important. 
The presence of amino acids that are approximately the same size as the native Glu
2.53(90) 
(Phe, 
Leu, Gln) may support an appropriate spacing of the TM helices that results in good 
expression of GnRHRs with unchanged affinity. This suggests a possible spacer role of the 
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Glu
2.53(90) 
that contributes to the overall fold of the GnRHR that is necessary for cell surface 
expression. If this is true, the small amino acid substitutions (Ala, Asn, Asp, Ser) for 
Glu
2.53(90) 
may have caused the TM helices to collapse towards one another, as small amino 
acids may not sufficiently fill the space of the Glu
2.53(90)
, resulting in a misfolded GnRHR that 
is targeted for degradation, instead of being trafficked to the plasma membrane to be 
expressed as a functional receptor protein.  
4.3. It is unlikely that Glu2.53(90) forms a salt-bridge with Lys121(3.32), but it is important 
for GnRHR expression 
Our results showing that mutant GnRHRs containing hydrophobic substitutions for 
Glu
2.53(90) 
are well expressed show that a salt-bridge interaction of the residue at the 2.53 locus 
is not necessary for robust GnRHR expression and suggest that Glu
2.53(90) 
may not form a salt-
bridge. However, it has been proposed that the decreased expression of the HH-associated 
Glu
2.53(90)
Lys mutant GnRHR results from the positive charge of the Lys at the 2.53 locus that 
disrupts an interaction with Lys
3.32(121) 
by causing an insurmountable charge repulsion within 
the TM helices (Blomenröhr et al., 2001; Conn & Ulloa-aguirre 2010; Conn & Ulloa-Aguirre 
2009; Janovick et al., 2011). If this is true, it would be expected that introduction of an Arg at 
the 2.53 locus would have a similar effect on GnRHR expression, as the guanidium groups of 
Arg side-chains within proteins are always positively charged (Betts & Russell 2007; Mayevu 
et al., 2015; Palczewski et al., 2000; Armstrong et al., 2016). The Glu
2.53(90)
Arg mutation 
preserved cell surface expression, even in the absence of a carboxy-terminal tail, as evidenced 
by the wild type-like maximal IP signalling. The preservation suggests that the Arg side-chain 
at the 2.53 locus is not in close apposition to Lys
3.32(121)
 and suggests that Glu
2.53(90) 
is not 
close enough to Lys
3.32(121) 
to form a salt-bridge in the wild type GnRHR. It also suggests that 
Arg makes interactions that stabilize GnRHR folding, but the decreased affinity suggests that 
Arg interactions distort the ligand binding pocket. Since other mutations show that the 
Glu
2.53(90) 
side-chain is not directly involved in ligand binding, the effect of the Arg 
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substitution at the 2.53 locus is likely to be indirect. The Arg side-chain is longer than 
Glu
2.53(90) 
and all other substitutions (Leu, Phe, Gln) that preserved GnRHR expression, 
suggesting that the presence of Arg may increase the distance between the TM helices, 
“pushing” the helices apart. This may cause a distortion in the configuration of the ligand 
binding pocket that could account for the decreased ligand binding affinity. A longer side-
chain being necessary at the 2.53 locus is also supported by the decreased affinity of the 
Glu
2.53(90)
Ala mutant GnRHR, which may result in a distortion to the ligand binding pocket, 
possibly caused by the TM helices collapsing towards one another. 
4.4. Trp6.48(280) may also be important for GnRHR structure  
Since our results for the Glu
2.53(90)
Arg mutant GnRHR exclude an interaction of 
Glu
2.53(90)
 with Lys
3.32(121)
, we investigated other potential intramolecular interactions that 
could account for the role of Glu
2.53(90) 
in GnRHR expression. Based on a proposed conserved 
water-mediated interaction of the residue at the 2.53 locus of class A GPCRs with the highly 
conserved Trp
6.48
 (Deupi, 2014; Deupi & Standfuss, 2011), we mutated the Trp
6.48(280) 
residue 
of the GnRHR. We confirmed lack of function of the Trp
6.48(280)
Ala mutant GnRHR (Coetsee 
et al., 2006) and showed recovery to wild type-like function by addition of a carboxy-terminal 
tail. Recovery of the function of this mutant suggests that, like Glu
2.53(90)
, the Trp
6.48(280) 
residue may be important for expression of the GnRHR, but is not a ligand-contacting residue. 
Coetsee et al. (2006) showed that a range of substitutions for Trp
6.48(280)
, including Ala, His, 
Gln and Met, resulted in severely decreased ligand binding, but all mutant GnRHRs showed 
binding affinity similar to wild type once recovered using the pharmacoperone, IN3. This 
suggests that Trp
6.48(280) 
does not directly interact with GnRH. We show that substitution of 
Trp
6.48(280) 
with Arg did not preserve GnRHR function in the absence of a carboxy-terminal 
tail. Thus, Arg disrupts folding, but when folding is recovered, there is decreased GnRH 
binding affinity suggesting that the receptor fold is distorted in the recovered mutant GnRHR.  
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4.5. The similar phenotypes of both Trp6.48(280)Arg and Glu2.53(90)Arg mutant GnRHRs 
suggest a similar disruption of the GnRHR 
Decreased GnRH binding affinity of the Trp
6.48(280)
Arg GnRHR with appended 
carboxy-terminal tail suggests that substituting Trp
6.48(280) 
with Arg affects the relative 
positioning of TM helices, causing a disruption of the configuration of the ligand binding 
pocket. The most recent analysis of intramolecular interactions in Class A GPCR crystal 
structures reported that the residues at the 2.53 and 6.48 loci have conserved interactions with 
adjacent residues, 3.35 and 3.36, in TM3 (Cvicek et al., 2016). Considering these conserved 
interactions, it is likely that Glu
2.53(90) 
directly contacts Ser
3.35(124) 
in TM3 of the GnRHR. This 
is supported by a mutagenesis study in which a Ser
3.35(124)
Ala
 
mutant GnRHR had wild-type-
like function, whereas, mutation of Ser
3.35(124) 
to Asp abolished receptor function (Betz et al., 
2006), suggesting that a repulsive interaction of the Asp with Glu
2.53(90) 
disrupts GnRHR 
folding.
 
The conserved interactions suggest that Trp
6.48(280) 
of the GnRHR would make a direct 
contact with Met
3.36(125)
, placing the side-chains of Glu
2.53(90) 
and Trp
6.48(280) 
within a shared 
environment. The Ser
3.35(124) 
and Met
3.36(125) 
residues are only three and four loci, i.e. one 
helical turn, away from the Lys
3.32(121)
, previously
 
proposed to form a salt-bridge interaction 
with Glu
2.53(90)
. These predictions are largely consistent with a homology model of the 
inactive human GnRHR from GPCRdb (figure 4.1, 
http://www.gpcrdb.org/structure/homology_models), which shows that Glu
2.53(90) 
is oriented 
toward Ser
3.35(124) 
in TM3, whereas Lys
3.32(121) 
is oriented away from Glu
2.53(90) 
but is 
positioned closer to Asp
2.61(98)
. This model also shows that Trp
6.48(280) 
of the inactive GnRHR 
is positioned in close proximity to Met
3.36(125)
 in TM3, and that Glu
2.53(90) 
and Trp
6.48(280) 
are in 
fact within a shared environment (figure 4.1). It is possible that modelling a negatively-
charged glutamate side-chain, rather than an uncharged glutamic acid side-chain may have 
biased the modelling process to create a salt-bridge interaction with the positively-charged 
Lys
3.32(121) 
instead of the highly conserved interaction of the 2.53 locus with the 3.35 locus. 
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Figure 4.1: Homology model of the inactive human GnRHR showing relative positions of residues 
Glu
2.53(90), 
Ser
3.35(124)
, Lys
3.32(121)
, Asp
2.61(98)
, Trp
6.48(280) 
and Met
3.36(125)
. This model was downloaded from the 
GPCRdb website (www.gpcrdb.org/structure/homology_models) and viewed using USCF Chimera software 
package, version 1.11.2, San Francisco to show the spatial positioning of Glu
2.53(90) 
(red) and Trp
6.48(280) 
(green) 
relative to the neighbouring residues; Ser
3.35(124) 
(light blue), Lys
3.32(121)
 (dark blue), Asp
2.61(98)
 (magenta), and 
Met
3.36(125)
 (yellow). 
 
Our results and the conserved intramolecular interactions with adjacent residues of 
TM3 are consistent with the proposal that Trp
6.48(280) 
and Glu
2.53(90) 
are part of a conserved 
“ligand sensing” region of class A GPCRs, where residues that are not a part of the ligand 
binding pocket are allosterically coupled to ligand binding (Madabushi et al., 2004). In 
conclusion, we have confirmed the importance of the Glu
2.53(90) 
in the function of the GnRHR 
and shown that this may be because it has a role as a space-filling residue in GnRHR folding. 
A negative charge of the side-chain is not necessary for GnRHR function and Glu
2.53(90) 
may 
be uncharged within the protein. Our results suggest that the Glu
2.53(90)
 probably does not form 
a salt-bridge interaction with Lys
3.32(121)
, but may occupy a space within the TM bundle of the 
GnRHR that is shared with Trp
6.48(280)
. Our results suggest that Glu
2.53(90) 
might not directly 
interact with Trp
6.48(280)
,
 
but that these two residues have a similar role in maintaining the 
overall GnRHR fold that contributes to stable cell surface expression of the receptor and 
configuration of the ligand binding pocket. We are currently involved in a collaboration that 
will hopefully yield molecular models to further integrate our mutagenesis data.  
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